<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <atom:link rel="self" type="application/rss+xml" href="https://escholarship.org/uc/ucla_radonc/rss"/>
    <ttl>720</ttl>
    <title>Recent ucla_radonc items</title>
    <link>https://escholarship.org/uc/ucla_radonc/rss</link>
    <description>Recent eScholarship items from UCLA Department of Radiation Oncology</description>
    <pubDate>Fri, 15 May 2026 06:33:30 +0000</pubDate>
    <item>
      <title>Therapeutic efficacy of dendritic cell vaccination in a novel syngeneic mouse model of diffuse hemispheric glioma, H3 G34-mutant</title>
      <link>https://escholarship.org/uc/item/5nv6j27n</link>
      <description>PurposeThe prognosis for pediatric high-grade gliomas associated with mutations in the H3-3A gene is very poor. To investigate whether tumor lysate-pulsed dendritic cells (DC) together with checkpoint blockade might be a potential treatment modality for diffuse hemispheric glioma H3 G34-mutant (DHG), we have developed a novel syngeneic mouse model.MethodsWe used the RCAS/tv-A system to target the expression of H3G34R and PDGFβ and knock out p53 in neural progenitors in C57BL/6 neonatal mice. Three independent cell lines were obtained that expressed transcripts associated with oligodendrocyte and interneuron lineages. Lethal tumor developed following intracranial injection.ResultsTwo cycles of DC vaccination with PD-1 blockade decreased tumor burden and increased survival. In treatment resistant tumors we found higher expression of several genes involved in remodeling the extracellular matrix compared with tumors from untreated animals, suggesting a causal link to resistance to...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5nv6j27n</guid>
      <pubDate>Wed, 22 Apr 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Owens, Geoffrey C</name>
      </author>
      <author>
        <name>Contreras, Erick M</name>
      </author>
      <author>
        <name>Kienzler, Jenny C</name>
      </author>
      <author>
        <name>Treger, Janet</name>
      </author>
      <author>
        <name>Soto, Horacio</name>
      </author>
      <author>
        <name>Orpilla, Joey R</name>
      </author>
      <author>
        <name>Qiao, Chloe</name>
      </author>
      <author>
        <name>Chang, Julia W</name>
      </author>
      <author>
        <name>Lee, Alexander</name>
      </author>
      <author>
        <name>Kim, Wi-Jin</name>
      </author>
      <author>
        <name>Sun, Matthew Z</name>
      </author>
      <author>
        <name>Peeters, Sophie F</name>
      </author>
      <author>
        <name>Bethel, Jacob A</name>
      </author>
      <author>
        <name>Kondajji, Aditya M</name>
      </author>
      <author>
        <name>Holland, Eric C</name>
      </author>
      <author>
        <name>Becher, Oren J</name>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Prins, Robert M</name>
      </author>
      <author>
        <name>Wang, Anthony C</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
    </item>
    <item>
      <title>Adversarial AI reveals mechanisms and treatments for disorders of consciousness</title>
      <link>https://escholarship.org/uc/item/2186k79t</link>
      <description>Understanding disorders of consciousness (DOC) remains one of the most challenging problems in neuroscience, hindered by the lack of experimental models for probing mechanisms or testing interventions. Here, to address this, we introduce a generative adversarial artificial intelligence (AI) framework that pits deep neural networks—trained to detect consciousness across more than 680,000 ten-second neuroelectrophysiology samples and validated on 565 patients, healthy volunteers and animals—against interpretable, machine learning-driven neural field models. This adversarial architecture produces biologically realistic simulations of both conscious and comatose brains that recapitulate empirical neurophysiological features across humans, monkeys, rats and bats. Without explicit programming, the AI model retrodicts known DOC responses to brain stimulation and generates testable predictions about the mechanisms of unconsciousness. Two such predictions are validated here: selective...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2186k79t</guid>
      <pubDate>Tue, 21 Apr 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Toker, Daniel</name>
      </author>
      <author>
        <name>Zheng, Zhong Sheng</name>
      </author>
      <author>
        <name>Thum, Jasmine A</name>
      </author>
      <author>
        <name>Guang, Jing</name>
      </author>
      <author>
        <name>Annen, Jitka</name>
      </author>
      <author>
        <name>Miyamoto, Hiroyuki</name>
      </author>
      <author>
        <name>Yamakawa, Kazuhiro</name>
      </author>
      <author>
        <name>Vespa, Paul M</name>
      </author>
      <author>
        <name>Laureys, Steven</name>
      </author>
      <author>
        <name>Schnakers, Caroline</name>
      </author>
      <author>
        <name>Bari, Ausaf A</name>
        <uri>https://orcid.org/0000-0002-5279-5023</uri>
      </author>
      <author>
        <name>Hudson, Andrew</name>
      </author>
      <author>
        <name>Pouratian, Nader</name>
      </author>
      <author>
        <name>Monti, Martin M</name>
        <uri>https://orcid.org/0000-0001-5511-3780</uri>
      </author>
    </item>
    <item>
      <title>Vaccine therapy for pediatric high-grade glioma: current landscape, challenges, and future directions</title>
      <link>https://escholarship.org/uc/item/1xw3b43p</link>
      <description>BackgroundPediatric high-grade gliomas (pHGG) are among the most aggressive childhood brain tumors, with limited treatment options and poor prognosis. Vaccine-based immunotherapy offers a promising strategy by leveraging tumor-specific or associated antigens to stimulate durable anti-tumor immune responses with minimal toxicity.DiscussionThis review outlines the scientific rationale for vaccine therapies in pHGG, detailing key targets such as glioma-associated antigens (EphA2, IL-13Rα2, survivin), driver mutation–derived neoantigens (H3.3K27M, TP53, IDH1), and viral antigens (CMV pp65). We evaluate current vaccine platforms, including peptide vaccines, dendritic cell vaccines, mRNA-based vaccines, and neoantigen-personalized approaches, highlighting early-phase clinical trial results that demonstrate safety and immunogenicity. Despite encouraging preliminary data, several challenges hinder clinical translation, including the distinct immune environment in the central nervous system,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1xw3b43p</guid>
      <pubDate>Mon, 16 Feb 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Harper, Stuart D</name>
      </author>
      <author>
        <name>Alderete, Jacob A</name>
      </author>
      <author>
        <name>Baisiwala, Shivani</name>
      </author>
      <author>
        <name>Bergsneider, Bianca H</name>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Wang, Anthony C</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
    </item>
    <item>
      <title>The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models.</title>
      <link>https://escholarship.org/uc/item/43f1z3qb</link>
      <description>Lung cancer, the leading cause of cancer mortality, exhibits diverse histologic subtypes and genetic complexities. Numerous preclinical mouse models have been developed to study lung cancer, but data from these models are disparate, siloed, and difficult to compare in a centralized fashion. In this study, we established the Lung Cancer Autochthonous Model Gene Expression Database (LCAMGDB), an extensive repository of 1,354 samples from 77 transcriptomic datasets covering 974 samples from genetically engineered mouse models (GEMM), 368 samples from carcinogen-induced models, and 12 samples from a spontaneous model. Meticulous curation and collaboration with data depositors produced a robust and comprehensive database, enhancing the fidelity of the genetic landscape it depicts. The LCAMGDB aligned 859 tumors from GEMMs with human lung cancer mutations, enabling comparative analysis and revealing a pressing need to broaden the diversity of genetic aberrations modeled in the GEMMs....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/43f1z3qb</guid>
      <pubDate>Wed, 10 Sep 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Cai, Ling</name>
      </author>
      <author>
        <name>Wu, Fangjiang</name>
      </author>
      <author>
        <name>Zhou, Qinbo</name>
      </author>
      <author>
        <name>Gao, Ying</name>
      </author>
      <author>
        <name>Yao, Bo</name>
      </author>
      <author>
        <name>DeBerardinis, Ralph J</name>
      </author>
      <author>
        <name>Acquaah-Mensah, George K</name>
      </author>
      <author>
        <name>Aidinis, Vassilis</name>
      </author>
      <author>
        <name>Beane, Jennifer E</name>
      </author>
      <author>
        <name>Biswal, Shyam</name>
      </author>
      <author>
        <name>Chen, Ting</name>
      </author>
      <author>
        <name>Concepcion-Crisol, Carla P</name>
      </author>
      <author>
        <name>Grüner, Barbara M</name>
      </author>
      <author>
        <name>Jia, Deshui</name>
      </author>
      <author>
        <name>Jones, Robert A</name>
      </author>
      <author>
        <name>Kurie, Jonathan M</name>
      </author>
      <author>
        <name>Lee, Min Gyu</name>
      </author>
      <author>
        <name>Lindahl, Per</name>
      </author>
      <author>
        <name>Lissanu, Yonathan</name>
      </author>
      <author>
        <name>Lorz, Corina</name>
      </author>
      <author>
        <name>MacPherson, David</name>
      </author>
      <author>
        <name>Martinelli, Rosanna</name>
      </author>
      <author>
        <name>Mazur, Pawel K</name>
      </author>
      <author>
        <name>Mazzilli, Sarah A</name>
      </author>
      <author>
        <name>Mii, Shinji</name>
      </author>
      <author>
        <name>Moll, Herwig P</name>
      </author>
      <author>
        <name>Moorehead, Roger A</name>
      </author>
      <author>
        <name>Morrisey, Edward E</name>
      </author>
      <author>
        <name>Ng, Sheng Rong</name>
      </author>
      <author>
        <name>Oser, Matthew G</name>
      </author>
      <author>
        <name>Pandiri, Arun R</name>
      </author>
      <author>
        <name>Powell, Charles A</name>
      </author>
      <author>
        <name>Ramadori, Giorgio</name>
      </author>
      <author>
        <name>Santos, Mirentxu</name>
      </author>
      <author>
        <name>Snyder, Eric L</name>
      </author>
      <author>
        <name>Sotillo, Rocio</name>
      </author>
      <author>
        <name>Su, Kang-Yi</name>
      </author>
      <author>
        <name>Taki, Tetsuro</name>
      </author>
      <author>
        <name>Taparra, Kekoa</name>
      </author>
      <author>
        <name>Tran, Phuoc T</name>
      </author>
      <author>
        <name>Xia, Yifeng</name>
      </author>
      <author>
        <name>van Veen, J Edward</name>
      </author>
      <author>
        <name>Winslow, Monte M</name>
      </author>
      <author>
        <name>Xiao, Guanghua</name>
      </author>
      <author>
        <name>Rudin, Charles M</name>
      </author>
      <author>
        <name>Oliver, Trudy G</name>
      </author>
      <author>
        <name>Xie, Yang</name>
      </author>
      <author>
        <name>Minna, John D</name>
      </author>
    </item>
    <item>
      <title>Stereotactic radiosurgery for brain metastases: evolving practice patterns from the national cancer database (2004–2020)</title>
      <link>https://escholarship.org/uc/item/3x04v0hv</link>
      <description>PurposeStereotactic radiosurgery (SRS) offers less neurotoxicity and comparable survival to whole-brain radiation therapy (WBRT) for brain metastases (BM). Current SRS practice patterns are understudied. We examined national trends in SRS and WBRT utilization.MethodsWe queried the National Cancer Database for patients with BM from twelve cancers (≥ 18 years; diagnosed 2004–2020) treated with radiotherapy. Patients were grouped by first-course radiotherapy modality (SRS:1–5 fractions; WBRT:5–15 fractions). Multivariable logistic regression assessed SRS predictors, adjusting for sociodemographic and clinical variables. A race*diagnosis year interaction evaluated temporal trends. Difference-in-differences analysis assessed Medicaid expansion impact.ResultsOf 89,984 patients, 24,174 (27%) received SRS. SRS utilization rose from 8 to 54% between 2004 and 2020 (P &amp;lt; 0.001). SRS was more likely in patients diagnosed in recent years (aOR = 3.85 [95% CI = 3.70–4.01]), who received prior...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3x04v0hv</guid>
      <pubDate>Wed, 10 Sep 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Shih, Jonathan J</name>
      </author>
      <author>
        <name>Jain, Bhav</name>
      </author>
      <author>
        <name>Patel, Rohan</name>
      </author>
      <author>
        <name>Jain, Urvish</name>
      </author>
      <author>
        <name>Lam, Miranda</name>
      </author>
      <author>
        <name>Chino, Fumiko</name>
      </author>
      <author>
        <name>Patel, Manali I</name>
      </author>
      <author>
        <name>Dee, Edward Christopher</name>
      </author>
      <author>
        <name>Pollom, Erqi</name>
      </author>
      <author>
        <name>Li, Gordon</name>
      </author>
      <author>
        <name>Taparra, Kekoa</name>
      </author>
    </item>
    <item>
      <title>Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment</title>
      <link>https://escholarship.org/uc/item/0kb0c018</link>
      <description>BACKGROUND: Residual or recurrent cancer after surgery but prior to adjuvant therapy occurs in a proportion of patients with head and neck cancer and may warrant treatment changes. 18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) may help to identify residual or recurrent disease but is not routinely obtained. We evaluated the relevance of postoperative FDG-PET/CT in this clinical context.
METHODS: This single-institution, retrospective study identified patients with head and neck cancer who underwent definitive surgery between January 1, 2013, and April 1, 2023, and received a postoperative FDG-PET/CT prior to adjuvant treatment. We measured the rates of management changes resulting from postoperative FDG-PET/CT findings and the association between having a postoperative FDG-PET/CT which resulted in a management change and oncologic outcomes with selected multivariable competing-risks and proportional hazards regressions.
RESULTS: Of 150 patients,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0kb0c018</guid>
      <pubDate>Wed, 27 Aug 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Courtney, P Travis</name>
      </author>
      <author>
        <name>Casillas, Jesus E Juarez</name>
      </author>
      <author>
        <name>Liu, Eulanca Y</name>
      </author>
      <author>
        <name>Sim, Myung-Shin</name>
      </author>
      <author>
        <name>Chau, Lydia W</name>
      </author>
      <author>
        <name>Lopez-Chicas, Rafael E</name>
      </author>
      <author>
        <name>St John, Maie A</name>
      </author>
      <author>
        <name>Abemayor, Elliot</name>
      </author>
      <author>
        <name>Blackwell, Keith E</name>
      </author>
      <author>
        <name>Chhetri, Dinesh K</name>
      </author>
      <author>
        <name>Gopen, Quinton S</name>
      </author>
      <author>
        <name>Kedeshian, Paul A</name>
      </author>
      <author>
        <name>Kerr, Rhorie P</name>
      </author>
      <author>
        <name>Lee, Jivianne K</name>
      </author>
      <author>
        <name>Nabili, Vishad</name>
      </author>
      <author>
        <name>Sercarz, Joel A</name>
      </author>
      <author>
        <name>Suh, Jeffrey D</name>
      </author>
      <author>
        <name>Wang, Marilene B</name>
        <uri>https://orcid.org/0000-0002-2799-6325</uri>
      </author>
      <author>
        <name>Wong, Deborah J</name>
      </author>
      <author>
        <name>Chai-Ho, Wanxing</name>
      </author>
      <author>
        <name>Jafarvand, Mahbod G</name>
      </author>
      <author>
        <name>Bahri, Shadfar</name>
      </author>
      <author>
        <name>Jank, Erika</name>
      </author>
      <author>
        <name>Reddy, Vishruth K</name>
      </author>
      <author>
        <name>Steinberg, Michael L</name>
      </author>
      <author>
        <name>Chin, Robert K</name>
      </author>
      <author>
        <name>Savjani, Ricky R</name>
        <uri>https://orcid.org/0000-0003-4763-2796</uri>
      </author>
    </item>
    <item>
      <title>Ray-Bundle Based X-ray Representation and Reconstruction: an Alternative to Classic Tomography on Voxelized Volumes</title>
      <link>https://escholarship.org/uc/item/5fw4b44x</link>
      <description>Tomography recovers internal volume from projection measurements. Formulated as inverse problems, classic computed tomography generally reconstructs attenuation property in a preset cartesian grid coordinate. While this is intuitive and convenient for digital display, such discretization leads to forward-backward projection inconsistency, and discrepancy between digital and effective resolution. We take a different perspective by considering the image volume as continuous and modelling forward projection as a hybrid continuous-to-discrete mapping from volume to detector elements, which we call "ray bundles". The ray bundle can be regarded as an unconventional heterogenous coordinate. Projections are modeled as line integrations along ray bundles in the continuous volume space and approximated by numerical integration using customized sample points. This modeling approach is conveniently supported with an implicit neural representation approach. By representing the volume as a...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5fw4b44x</guid>
      <pubDate>Wed, 20 Aug 2025 00:00:00 +0000</pubDate>
      <author>
        <name>He, Yuanwei</name>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
    </item>
    <item>
      <title>An ultra-high performance parallel (UHPP) framework for complex 4π radiotherapy planning</title>
      <link>https://escholarship.org/uc/item/77g6v6zk</link>
      <description>&lt;i&gt;Purpose&lt;/i&gt;. In radiotherapy, dose distribution conformity and compactness are critical to patient outcomes. Advanced techniques like4πradiotherapy leverage non-coplanar beams for superior dosimetry by exploring additional degrees of freedom. However,4πplanning is computationally intensive due to large dose-loading matrices for candidate beams. This work presents an ultra-high performance parallel (UHPP) framework to accelerate high-dimensional treatment planning.&lt;i&gt;Methods&lt;/i&gt;. For dose calculation, we developed: (1) a two-step total energy released per unit mass (TERMA) computation module calculating the TERMA array once per beam, enabling reuse across convolution directions; (2) a synchronized dose calculation module based on collapsed-cone convolution superposition (CCCS), arranging rays in dedicated sequences to preserve thread efficiency and minimize memory access; (3) a scattering-based coordinate transformation mapping dose from beamlet to patient Cartesian coordinates,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/77g6v6zk</guid>
      <pubDate>Thu, 14 Aug 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Xu, Qifan</name>
        <uri>https://orcid.org/0000-0002-7155-9552</uri>
      </author>
      <author>
        <name>Lyu, Qihui</name>
      </author>
      <author>
        <name>Jiang, Lu</name>
      </author>
      <author>
        <name>Jing, Shusen</name>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
      <author>
        <name>Sheng, Ke</name>
      </author>
    </item>
    <item>
      <title>Cold atmospheric plasma effectively kills chordoma cells through induction of intracellular reactive oxygen species</title>
      <link>https://escholarship.org/uc/item/7p54h7kn</link>
      <description>Chordomas remain one of the most difficult-to-treat of skull base tumors. The best chance of survival and cure to date is with en bloc radical surgical resection, followed by adjuvant radiotherapy. Oftentimes, tumor infiltration into functionally critical, or difficult-to-access areas, precludes optimal resection. The median overall survival for these tumors is 116 months. Cold atmospheric plasma (CAP) is generated by applying a high voltage electric field to helium or argon feed gases, resulting in reactive atmospheric species. Over the past decade, CAP has been applied experimentally in a number of oncologic conditions and has demonstrated anti-tumor effects both in vitro and in vivo. Additionally, CAP has been shown to increase cancer cells’ sensitivity to radiation and could therefore be a useful tool in improving chordoma recurrence rates as an intraoperative adjuvant therapy to the current standard of care. To date, there are no studies in the literature examining the efficacy...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7p54h7kn</guid>
      <pubDate>Wed, 30 Jul 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Peeters, Sophie</name>
      </author>
      <author>
        <name>Wu, Peter B</name>
      </author>
      <author>
        <name>Haist, Blake</name>
      </author>
      <author>
        <name>Armellini, Amber</name>
      </author>
      <author>
        <name>Kim, Wi Jin</name>
      </author>
      <author>
        <name>Chen, Zhitong</name>
      </author>
      <author>
        <name>Obenchain, Richard</name>
      </author>
      <author>
        <name>Ayad, George</name>
      </author>
      <author>
        <name>Ge, Weihong</name>
      </author>
      <author>
        <name>Bhaduri, Aparna</name>
      </author>
      <author>
        <name>Sabiston, Graeme</name>
      </author>
      <author>
        <name>Prins, Robert M</name>
      </author>
      <author>
        <name>Wirz, Richard</name>
      </author>
      <author>
        <name>Wang, Anthony C</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
    </item>
    <item>
      <title>Cerebrovascular longitudinal atlas: Changes in cerebral arteries in unruptured intracranial aneurysm patients followed with MRA</title>
      <link>https://escholarship.org/uc/item/5933176f</link>
      <description>BACKGROUND: Patterns of change in cerebrovascular (CV) morphology associated with aging are highly relevant to the incidence and progression of CV disease, particularly stroke. Intracranial aneurysms (IA), a leading cause of hemorrhagic stroke, are linked with factors such as blood flow, arterial stiffness, and inflammation that may also drive other changes in CV morphology. We worked with a cohort of longitudinally-imaged IA patients to construct the first longitudinal atlas of CV morphology and studied its relationship with disease.
METHODS: 110 IA patients, ranging from 19 to 84&amp;nbsp;years old at IA detection, were monitored using 3D magnetic resonance angiography (MRA) for a mean of 6.11 (2.60) years with 3.6 (1.3) scans per patient. Using 405 image studies, we applied a machine learning diffeomorphic shape analysis to construct a longitudinal atlas of the cerebral arteries which defined a general trajectory of CV morphological change vs. age. This was paired with a centerline...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5933176f</guid>
      <pubDate>Fri, 11 Apr 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Chien, Aichi</name>
      </author>
      <author>
        <name>Vinuela, Fernando</name>
      </author>
      <author>
        <name>Szeder, Viktor</name>
      </author>
      <author>
        <name>Colby, Geoffrey</name>
        <uri>https://orcid.org/0000-0002-3376-0933</uri>
      </author>
      <author>
        <name>Jahan, Reza</name>
      </author>
      <author>
        <name>Wang, Anthony</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
      <author>
        <name>Tateshima, Satoshi</name>
        <uri>https://orcid.org/0000-0003-0060-0930</uri>
      </author>
      <author>
        <name>Duckwiler, Gary</name>
      </author>
      <author>
        <name>Salamon, Noriko</name>
        <uri>https://orcid.org/0000-0002-3520-9467</uri>
      </author>
    </item>
    <item>
      <title>ECG‐free cine MRI with data‐driven clustering of cardiac motion for quantification of ventricular function</title>
      <link>https://escholarship.org/uc/item/82s8v3fp</link>
      <description>BACKGROUND: Despite the widespread use of cine MRI for evaluation of cardiac function, existing real-time methods do not easily enable quantification of ventricular function. Moreover, segmented cine MRI assumes periodicity of cardiac motion. We aim to develop a self-gated, cine MRI acquisition scheme with data-driven cluster-based binning of cardiac motion.
METHODS: A Cartesian golden-step balanced steady-state free precession sequence with sorted k-space ordering was designed. Image data were acquired with breath-holding. Principal component analysis and k-means clustering were used for binning of cardiac phases. Cluster compactness in the time dimension was assessed using temporal variability, and dispersion in the spatial dimension was assessed using the Caliński-Harabasz index. The proposed and the reference electrocardiogram (ECG)-gated cine methods were compared using a four-point image quality score, SNR and CNR values, and Bland-Altman analyses of ventricular function.
RESULTS:...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/82s8v3fp</guid>
      <pubDate>Wed, 9 Apr 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Ming, Zhengyang</name>
      </author>
      <author>
        <name>Pogosyan, Arutyun</name>
      </author>
      <author>
        <name>Gao, Chang</name>
      </author>
      <author>
        <name>Colbert, Caroline M</name>
      </author>
      <author>
        <name>Wu, Holden H</name>
        <uri>https://orcid.org/0000-0002-2585-5916</uri>
      </author>
      <author>
        <name>Finn, J Paul</name>
        <uri>https://orcid.org/0000-0002-4534-7572</uri>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
      <author>
        <name>Hu, Peng</name>
      </author>
      <author>
        <name>Christodoulou, Anthony G</name>
        <uri>https://orcid.org/0000-0002-9334-8684</uri>
      </author>
      <author>
        <name>Nguyen, Kim‐Lien</name>
      </author>
    </item>
    <item>
      <title>Cerebellar Vascular Malformation of Unknown Aetiology with Recent COVID-19 Infection</title>
      <link>https://escholarship.org/uc/item/11n7730c</link>
      <description>Cerebellar Vascular Malformation of Unknown Aetiology with Recent COVID-19 Infection</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/11n7730c</guid>
      <pubDate>Wed, 9 Apr 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Chang, Diana</name>
      </author>
      <author>
        <name>Tateshima, Satoshi</name>
        <uri>https://orcid.org/0000-0003-0060-0930</uri>
      </author>
      <author>
        <name>Han, Karam</name>
      </author>
      <author>
        <name>Mirbaha, Hilda</name>
      </author>
      <author>
        <name>Beaman, Charles</name>
      </author>
      <author>
        <name>Colby, Geoffrey P</name>
        <uri>https://orcid.org/0000-0002-3376-0933</uri>
      </author>
      <author>
        <name>Salamon, Noriko</name>
        <uri>https://orcid.org/0000-0002-3520-9467</uri>
      </author>
      <author>
        <name>Vinters, Harry V</name>
      </author>
      <author>
        <name>Wang, Anthony C</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
    </item>
    <item>
      <title>Trends in racial and ethnic disparities in the health-related quality of life of older adults with breast cancer: a SEER-MHOS national database study</title>
      <link>https://escholarship.org/uc/item/54s9f9g6</link>
      <description>PurposeTo examine racial and ethnic disparities in Health-Related Quality of Life (HRQOL) in older adults with breast cancer, both pre- and post-diagnosis.MethodsUsing the SEER-MHOS database, we included patients ≥ 65 years old with breast cancer who completed the Health Outcomes Survey within 24 months pre- and post-diagnosis, and who were non-Hispanic White, non-Hispanic Asian or Pacific Islander, non-Hispanic Black or African American, or Hispanic. HRQOL data was measured via the Physical and Mental Component Summary (PCS, MCS). Univariable and multivariable linear regression models were fitted to assess for potential disparities between races and ethnicities.ResultsOn univariable regression models, a numerical drop in mean scores of PCS and MCS was found among all racial/ethnic groups between pre- and post-diagnosis. Among patients in the pre-diagnosis cohort who would be diagnosed with stage IV breast cancer, race was found to be a predictor of PCS with overall significance...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/54s9f9g6</guid>
      <pubDate>Mon, 7 Apr 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Karimi-Mostowfi, Nicki</name>
      </author>
      <author>
        <name>Chu, Fang-I</name>
      </author>
      <author>
        <name>Wu, Trudy C</name>
        <uri>https://orcid.org/0000-0002-9475-2072</uri>
      </author>
      <author>
        <name>Farrell, Matthew J</name>
        <uri>https://orcid.org/0000-0003-4810-6253</uri>
      </author>
      <author>
        <name>Akingbemi, Wisdom</name>
      </author>
      <author>
        <name>Raldow, Ann C</name>
      </author>
    </item>
    <item>
      <title>Radiation-induced cellular plasticity primes glioblastoma for forskolin-mediated differentiation</title>
      <link>https://escholarship.org/uc/item/8t32k1p9</link>
      <description>Glioblastoma (GBM) is the deadliest brain cancer in adults, and all patients succumb to the tumor. While surgery followed by chemoradiotherapy delays disease progression, these treatments do not lead to tumor control, and targeted therapies or biologics have failed to further improve survival. Utilizing a transient radiation-induced state of multipotency, we used the adenylcyclase activator forskolin to alter the fate of irradiated glioma cells. The effects of the combined treatment on neuronal marker expression, cell cycle distribution, and proliferation were studied. Gene expression profiling was conducted using bulk RNA-seq. Changes in cell populations were investigated using single-cell RNA-seq. Effects on glioma stem cells (GSCs) were studied in extreme limiting dilution assays, and the effects on median survival were studied in both syngeneic and PDOX mouse models of GBM. The combined treatment induced the expression of neuronal markers in glioma cells, reduced proliferation,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8t32k1p9</guid>
      <pubDate>Wed, 2 Apr 2025 00:00:00 +0000</pubDate>
      <author>
        <name>He, Ling</name>
        <uri>https://orcid.org/0000-0002-8692-7530</uri>
      </author>
      <author>
        <name>Azizad, Daria</name>
      </author>
      <author>
        <name>Bhat, Kruttika</name>
      </author>
      <author>
        <name>Ioannidis, Angeliki</name>
      </author>
      <author>
        <name>Hoffmann, Carter J</name>
      </author>
      <author>
        <name>Arambula, Evelyn</name>
      </author>
      <author>
        <name>Eghbali, Mansoureh</name>
      </author>
      <author>
        <name>Bhaduri, Aparna</name>
      </author>
      <author>
        <name>Kornblum, Harley I</name>
      </author>
      <author>
        <name>Pajonk, Frank</name>
      </author>
    </item>
    <item>
      <title>Metastatic secondary gliosarcoma: patient series</title>
      <link>https://escholarship.org/uc/item/70r468k4</link>
      <description>BACKGROUND: Gliosarcoma is a rare and highly malignant cancer of the central nervous system with the ability to metastasize. Secondary gliosarcoma, or the evolution of a spindle cell-predominant tumor after the diagnosis of a World Health Organization grade IV glioblastoma, has also been shown to metastasize. There is little information on metastatic secondary gliosarcoma.
OBSERVATIONS: The authors present a series of 7 patients with previously diagnosed glioblastoma presenting with recurrent tumor and associated metastases with repeat tissue diagnosis consistent with gliosarcoma. The authors describe the clinical, imaging, and pathological characteristics in addition to carrying out a systematic review on metastases in secondary gliosarcoma.
LESSONS: The present institutional series and the systematic review of the literature show that metastatic secondary gliosarcoma is a highly aggressive disease with a poor prognosis.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/70r468k4</guid>
      <pubDate>Wed, 2 Apr 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Baisiwala, Shivani</name>
      </author>
      <author>
        <name>Ko, Myungjun</name>
      </author>
      <author>
        <name>Zubair, Humza</name>
      </author>
      <author>
        <name>Li, Kevin</name>
      </author>
      <author>
        <name>Vivas, Andrew C</name>
      </author>
      <author>
        <name>Everson, Richard</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Liau, Linda</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Bari, Ausaf</name>
      </author>
      <author>
        <name>Patel, Kunal S</name>
      </author>
    </item>
    <item>
      <title>Travel Burden of Radiation Therapy in the Philippines</title>
      <link>https://escholarship.org/uc/item/5q74p6x4</link>
      <description>Purpose: Travel burden negatively impacts the stage at diagnosis, treatment, outcome, and quality of life among patients with cancer. Travel burden-quantified as distance, time, and cost of travel-is magnified in low- and middle-income countries like the Philippines, where radiation therapy (RT) resources are lacking and are inequitably distributed.
Methods and Materials: We compared Philippine Radiation Oncology Society data and the population census to determine the distribution and density of RT facilities across the country's 17 regions. For distance and travel time, we used the Google Maps route planner to determine the best routes from each province to the nearest private and government RT facility. Travel cost was calculated by multiplying distance by the local price of diesel per liter and the mean fuel economy of passenger vehicles in the Philippines.
Results: There are only 54 RT facilities in the Philippines (0.5 per 1 million population). More than a third are in the...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5q74p6x4</guid>
      <pubDate>Wed, 2 Apr 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Eala, Michelle Ann B</name>
      </author>
      <author>
        <name>Maslog, Ethan Angelo S</name>
      </author>
      <author>
        <name>Alberto, Nicole Rose I</name>
      </author>
      <author>
        <name>Alberto, Isabelle Rose I</name>
      </author>
      <author>
        <name>Ho, Frances Dominique V</name>
      </author>
      <author>
        <name>Dee, Edward Christopher</name>
      </author>
      <author>
        <name>Raldow, Ann</name>
      </author>
      <author>
        <name>Cereno, Reno Eufemon</name>
      </author>
    </item>
    <item>
      <title>Metabolic differences in breast cancer stem cells and differentiated progeny</title>
      <link>https://escholarship.org/uc/item/92z5s1cb</link>
      <description>In general, tumor cells display a more glycolytic phenotype compared to the corresponding normal tissue. However, it is becoming increasingly clear that tumors are composed of a heterogeneous population of cells. Breast cancers are organized in a hierarchical manner, with the breast cancer stem cells (BCSCs) at the top of the hierarchy. Here, we investigate the metabolic phenotype of BCSCs and their differentiated progeny. In addition, we determine the effect of radiation on the metabolic state of these two cell populations. Luminal, basal, and claudin-low breast cancer cell lines were propagated as mammospheres enriched in BCSCs. Lactate production, glucose consumption, and ATP content were compared with differentiated cultures. A metabolic flux analyzer was used to determine the oxygen consumption, extracellular acidification rates, maximal mitochondria capacity, and mitochondrial proton leak. The effect of radiation treatment of the metabolic phenotype of each cell population...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/92z5s1cb</guid>
      <pubDate>Thu, 27 Mar 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Vlashi, Erina</name>
      </author>
      <author>
        <name>Lagadec, Chann</name>
      </author>
      <author>
        <name>Vergnes, Laurent</name>
      </author>
      <author>
        <name>Reue, Karen</name>
      </author>
      <author>
        <name>Frohnen, Patricia</name>
      </author>
      <author>
        <name>Chan, Mabel</name>
      </author>
      <author>
        <name>Alhiyari, Yazeed</name>
      </author>
      <author>
        <name>Dratver, Milana Bochkur</name>
      </author>
      <author>
        <name>Pajonk, Frank</name>
      </author>
    </item>
    <item>
      <title>An implicit neural deformable ray model for limited and sparse view‐based spatiotemporal reconstruction</title>
      <link>https://escholarship.org/uc/item/3nh6976x</link>
      <description>BACKGROUND: Continuous spatiotemporal volumetric reconstruction is highly valuable, especially in radiation therapy, where tracking and calculating actual exposure during a treatment session is critical. This allows for accurate analysis of treatment outcomes, including patient response and toxicity in relation to delivered doses. However, continuous 4D imaging during radiotherapy is often unavailable due to radiation exposure concerns and hardware limitations. Most setups are limited to acquiring intermittent portal projections or images between treatment beams.
PURPOSE: This study addresses the challenge of spatiotemporal reconstruction from limited views by reconstructing patient-specific volume with as low as 20 input views and continuous-time dynamic volumes from only two orthogonal x-ray projections.
METHODS: We introduce a novel implicit neural deformable ray (INDeR) model that uses a ray bundle coordinate system, embedding sparse view measurements into an implicit neural...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3nh6976x</guid>
      <pubDate>Wed, 26 Mar 2025 00:00:00 +0000</pubDate>
      <author>
        <name>He, Yuanwei</name>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
    </item>
    <item>
      <title>In-clinic Versus Online Recruitment of Women With a History of Cervical Intraepithelial Neoplasia or Cervical Cancer to a Smoking Cessation Trial: A Post hoc Comparison of Participant Characteristics, Study Retention, and Cessation Outcomes</title>
      <link>https://escholarship.org/uc/item/1570193d</link>
      <description>INTRODUCTION: Recruiting special populations to smoking cessation trials is challenging and approaches beyond in-clinic recruitment may be beneficial. This secondary analysis of data from a smoking cessation RCT for individuals with a history of cervical cancer or cervical intraepithelial neoplasia (CIN) explored differences associated with in-clinic vs. online recruitment.
AIMS AND METHODS: Participants were recruited from clinics within a university-based NCI-designated cancer center (n = 87) and online nationally via Facebook (n = 115). Baseline measures included sociodemographics, smoking history, and cancer or CIN history. Study retention and smoking abstinence were assessed 12 months post-baseline. Group differences in baseline characteristics were evaluated. Retention and abstinence were evaluated while controlling for group differences and predictors.
RESULTS: Participants recruited online (vs. in-clinic) had higher educational attainment (p = .01) and health literacy...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1570193d</guid>
      <pubDate>Thu, 20 Mar 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Fennell, Bethany Shorey</name>
      </author>
      <author>
        <name>Jones, Sarah R</name>
      </author>
      <author>
        <name>Sutton, Steven K</name>
      </author>
      <author>
        <name>Hoogland, Charles E</name>
      </author>
      <author>
        <name>Cottrell-Daniels, Cherell</name>
      </author>
      <author>
        <name>Wetter, David W</name>
      </author>
      <author>
        <name>Shih, Ya-Chen Tina</name>
        <uri>https://orcid.org/0000-0002-9454-4337</uri>
      </author>
      <author>
        <name>Simmons, Vani N</name>
      </author>
      <author>
        <name>Stephens, Yesenia P</name>
      </author>
      <author>
        <name>Vidrine, Damon J</name>
      </author>
      <author>
        <name>Vidrine, Jennifer I</name>
      </author>
    </item>
    <item>
      <title>Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial</title>
      <link>https://escholarship.org/uc/item/3gj4p5p9</link>
      <description>INTRODUCTION: Prior attempts to escalate radiation dose for non-small cell lung cancer (NSCLC) have not improved survival. Given the high risk for cardiopulmonary toxicity with treatment and heterogenous presentation of locally advanced NSCLC, it is unlikely that a single dose regimen is optimal for all patients. This phase I/II trial aims to evaluate a novel treatment approach where the level of accelerated hypofractionation is determined by the predicted toxicity from dose to organs at risk (OARs).
METHODS: Patients ≥ 18 years old with lung cancer planned for fractionated radiotherapy to the lung with concurrent chemotherapy will be eligible. Radiation therapy (RT) will be delivered to a total dose of 60 to 66 Gy in 30, 25, or 20 fractions depending on the ability to meet constraints to key organs at risk including the lungs, heart, and esophagus. The primary endpoint is high grade pulmonary, esophageal, or cardiac toxicity. A Bayesian optimized design is used to determine stopping...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3gj4p5p9</guid>
      <pubDate>Tue, 18 Mar 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Hui, Caressa</name>
        <uri>https://orcid.org/0000-0002-3864-4720</uri>
      </author>
      <author>
        <name>Brown, Eleanor</name>
      </author>
      <author>
        <name>Wong, Samantha</name>
      </author>
      <author>
        <name>Das, Millie</name>
      </author>
      <author>
        <name>Wakelee, Heather</name>
      </author>
      <author>
        <name>Neal, Joel</name>
      </author>
      <author>
        <name>Ramchandran, Kavitha</name>
      </author>
      <author>
        <name>Myall, Nathaniel J</name>
      </author>
      <author>
        <name>Pham, Daniel</name>
      </author>
      <author>
        <name>Xing, Lei</name>
      </author>
      <author>
        <name>Yang, Yong</name>
      </author>
      <author>
        <name>Kovalchuk, Nataliya</name>
      </author>
      <author>
        <name>Yuan, Ying</name>
      </author>
      <author>
        <name>Lu, Ying</name>
      </author>
      <author>
        <name>Xiang, Michael</name>
        <uri>https://orcid.org/0000-0003-0170-9321</uri>
      </author>
      <author>
        <name>Chin, Alex</name>
      </author>
      <author>
        <name>Diehn, Maximilian</name>
        <uri>https://orcid.org/0000-0003-2032-0581</uri>
      </author>
      <author>
        <name>Loo, Billy W</name>
      </author>
      <author>
        <name>Vitzthum, Lucas K</name>
      </author>
    </item>
    <item>
      <title>Analysis of Oncology and Radiation Therapy Representation on the National Board of Medical Examiners Official Practice Material for the United States National Standardized Medical Board Examinations</title>
      <link>https://escholarship.org/uc/item/2bn2v0bn</link>
      <description>Radiation therapy (RT) is a critical component of multidisciplinary cancer care, but has inconsistent curricular exposure. We characterize the radiation oncology (RO) content on the standardized undergraduate medical examinations by comparing its context and prevalence with other domains in oncology. National Board of Medical Examiners (NBME) self-assessments and sample questions for the United States Medical Licensing Exam (USMLE) Steps 1–3 and NBME clinical science shelf examinations were accessed (n = 3878). Questions were inductively analyzed for content pertaining to oncology and treatment modalities of RT, systemic therapy (ST), and surgical intervention (SI). Questions were coded using USMLE Physician Tasks/Competencies and thematic analysis. Descriptive statistics and analyses using the Kruskal–Wallis test are reported. A total of 337 questions (8.6%) within the USMLE and shelf exams included oncology content, with 101 questions (2.6%) referencing at least one cancer treatment...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2bn2v0bn</guid>
      <pubDate>Sat, 1 Mar 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Mahoney, Mary T</name>
      </author>
      <author>
        <name>Linkowski, Lauren C</name>
      </author>
      <author>
        <name>Wu, Trudy C</name>
        <uri>https://orcid.org/0000-0002-9475-2072</uri>
      </author>
      <author>
        <name>Chen, Jie Jane</name>
        <uri>https://orcid.org/0000-0002-5380-4825</uri>
      </author>
      <author>
        <name>Neilsen, Beth K</name>
      </author>
      <author>
        <name>Thompson, Petria S</name>
      </author>
      <author>
        <name>Mix, Michael D</name>
      </author>
      <author>
        <name>Sura, Karna T</name>
      </author>
      <author>
        <name>Mattes, Malcolm D</name>
      </author>
    </item>
    <item>
      <title>A Retrospective Analysis of the First Clinical 5DCT Workflow</title>
      <link>https://escholarship.org/uc/item/4q94g4jr</link>
      <description>BACKGROUND/OBJECTIVES: 5DCT was first proposed in 2005 as a motion-compensated CT simulation approach for radiotherapy treatment planning to avoid sorting artifacts that arise in 4DCT when patients breathe irregularly. Since March 2019, 5DCT has been clinically implemented for routine use at our institution to leverage this technological advantage. The clinical workflow includes a quality assurance report that describes the output of primary workflow steps. This study reports on the challenges and quality of the clinical 5DCT workflow using these quality assurance reports.
METHODS: We evaluated all thoracic 5DCT simulation datasets consecutively acquired at our institution between March 2019 and December 2022 for thoracic radiotherapy treatment planning. The 5DCT datasets utilized motion models constructed from 25 fast-helical free-breathing computed tomography (FHFBCTs) with simultaneous respiratory bellows signal monitoring to reconstruct individual, user-specified breathing-phase...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4q94g4jr</guid>
      <pubDate>Fri, 28 Feb 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Lauria, Michael</name>
        <uri>https://orcid.org/0000-0003-1194-0148</uri>
      </author>
      <author>
        <name>Kim, Minji</name>
      </author>
      <author>
        <name>O’Connell, Dylan</name>
      </author>
      <author>
        <name>Lao, Yi</name>
      </author>
      <author>
        <name>Miller, Claudia R</name>
      </author>
      <author>
        <name>Naumann, Louise</name>
      </author>
      <author>
        <name>Boyle, Peter</name>
      </author>
      <author>
        <name>Raldow, Ann</name>
      </author>
      <author>
        <name>Lee, Alan</name>
      </author>
      <author>
        <name>Savjani, Ricky R</name>
        <uri>https://orcid.org/0000-0003-4763-2796</uri>
      </author>
      <author>
        <name>Moghanaki, Drew</name>
      </author>
      <author>
        <name>Low, Daniel A</name>
      </author>
    </item>
    <item>
      <title>Distinct Urinary Metabolite Signatures Mirror In Vivo Oxidative Stress-Related Radiation Responses in Mice</title>
      <link>https://escholarship.org/uc/item/2jn557jr</link>
      <description>Exposure to ionizing radiation disrupts metabolic pathways and causes oxidative stress, which can lead to organ damage. In this study, urinary metabolites from mice exposed to high-dose and low-dose whole-body irradiation (WBI HDR, WBI LDR) or partial-body irradiation (PBI BM2.5) were analyzed using targeted and untargeted metabolomics approaches. Significant metabolic changes particularly in oxidative stress pathways were observed on Day 2 post-radiation. By Day 30, the WBI HDR group showed persistent metabolic dysregulation, while the WBI LDR and PBI BM2.5 groups were similar to control mice. Machine learning models identified metabolites that were predictive of the type of radiation exposure with high accuracy, highlighting their potential use as biomarkers for radiation damage and oxidative stress.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2jn557jr</guid>
      <pubDate>Thu, 27 Feb 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Li, Yaoxiang</name>
      </author>
      <author>
        <name>Bansal, Shivani</name>
      </author>
      <author>
        <name>Singh, Baldev</name>
      </author>
      <author>
        <name>Jayatilake, Meth M</name>
      </author>
      <author>
        <name>Klotzbier, William</name>
      </author>
      <author>
        <name>Boerma, Marjan</name>
      </author>
      <author>
        <name>Lee, Mi-Heon</name>
      </author>
      <author>
        <name>Hack, Jacob</name>
      </author>
      <author>
        <name>Iwamoto, Keisuke S</name>
      </author>
      <author>
        <name>Schaue, Dörthe</name>
      </author>
      <author>
        <name>Cheema, Amrita K</name>
      </author>
    </item>
    <item>
      <title>Longitudinal varying coefficient single-index model with censored covariates</title>
      <link>https://escholarship.org/uc/item/9j46p5z3</link>
      <description>It is of interest to health policy research to estimate the population-averaged longitudinal medical cost trajectory from initial cancer diagnosis to death, and understand how the trajectory curve is affected by patient characteristics. This research question leads to a number of statistical challenges because the longitudinal cost data are often non-normally distributed with skewness, zero-inflation, and heteroscedasticity. The trajectory is nonlinear, and its length and shape depend on survival, which are subject to censoring. Modeling the association between multiple patient characteristics and nonlinear cost trajectory curves of varying lengths should take into consideration parsimony, flexibility, and interpretation. We propose a novel longitudinal varying coefficient single-index model. Multiple patient characteristics are summarized in a single-index, representing a patient's overall propensity for healthcare use. The effects of this index on various segments of the cost...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9j46p5z3</guid>
      <pubDate>Wed, 26 Feb 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Wang, Shikun</name>
      </author>
      <author>
        <name>Ning, Jing</name>
      </author>
      <author>
        <name>Xu, Ying</name>
      </author>
      <author>
        <name>Shih, Ya-Chen Tina</name>
        <uri>https://orcid.org/0000-0002-9454-4337</uri>
      </author>
      <author>
        <name>Shen, Yu</name>
      </author>
      <author>
        <name>Li, Liang</name>
      </author>
    </item>
    <item>
      <title>Characterization of facial nerve outcomes following radiosurgery for vestibular schwannoma: a meta-analysis</title>
      <link>https://escholarship.org/uc/item/9f82v4q7</link>
      <description>PurposeGamma Knife radiosurgery (GKRS) is a precise and efficacious treatment modality for vestibular schwannoma (VS) with favorable cranial nerve preservation rates. This study aims to better characterize facial nerve (FN) outcomes in VS after GKRS.MethodsA query of six medical databases was conducted following PRISMA guidelines. Eligible studies exclusively reported VS managed with single-fraction GKRS and included House-Brackmann (HB) scale assessments prior to and following GKRS. Data was analyzed using random-effects modeling, and FN preservation was defined as HB I or II at last follow-up.ResultsData was analyzed from 15 articles with 3,155 patients at an mean age of 55.0&amp;nbsp;years. Mean tumor volume, radiation dose, follow-up, tumor control, and hearing preservation were 4.28 cm3, 13.3&amp;nbsp;Gy, 59.4&amp;nbsp;months, 92.7%, and 62.6%, respectively. The pooled FN preservation rate was 92.9%. Mean preoperative tumor volume &amp;gt; 2.5 cm3 and age &amp;gt; 60&amp;nbsp;years were significantly...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9f82v4q7</guid>
      <pubDate>Fri, 14 Feb 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Hovis, Gabrielle EA</name>
      </author>
      <author>
        <name>Chandla, Anubhav</name>
      </author>
      <author>
        <name>Pandey, Aryan</name>
      </author>
      <author>
        <name>Teton, Zoe</name>
      </author>
      <author>
        <name>Yang, Isaac</name>
        <uri>https://orcid.org/0000-0002-5176-5615</uri>
      </author>
    </item>
    <item>
      <title>Toward a Computable Phenotype for Determining Eligibility of Lung Cancer Screening Using Electronic Health Records</title>
      <link>https://escholarship.org/uc/item/7mk703tv</link>
      <description>PURPOSE: Lung cancer screening (LCS) has the potential to reduce mortality and detect lung cancer at its early stages, but the high false-positive rate associated with low-dose computed tomography (LDCT) for LCS acts as a barrier to its widespread adoption. This study aims to develop computable phenotype (CP) algorithms on the basis of electronic health records (EHRs) to identify individual's eligibility for LCS, thereby enhancing LCS utilization in real-world settings.
MATERIALS AND METHODS: The study cohort included 5,778 individuals who underwent LDCT for LCS from 2012 to 2022, as recorded in the University of Florida Health Integrated Data Repository. CP rules derived from LCS guidelines were used to identify potential candidates, incorporating both structured EHR and clinical notes analyzed via natural language processing. We then conducted manual reviews of 453 randomly selected charts to refine and validate these rules, assessing CP performance using metrics, for example,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7mk703tv</guid>
      <pubDate>Fri, 14 Feb 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Yang, Shuang</name>
      </author>
      <author>
        <name>Huang, Yu</name>
      </author>
      <author>
        <name>Lou, Xiwei</name>
      </author>
      <author>
        <name>Lyu, Tianchen</name>
      </author>
      <author>
        <name>Wei, Ruoqi</name>
      </author>
      <author>
        <name>Mehta, Hiren J</name>
      </author>
      <author>
        <name>Wu, Yonghui</name>
      </author>
      <author>
        <name>Alvarado, Michelle</name>
      </author>
      <author>
        <name>Salloum, Ramzi G</name>
      </author>
      <author>
        <name>Braithwaite, Dejana</name>
      </author>
      <author>
        <name>Huo, Jinhai</name>
      </author>
      <author>
        <name>Shih, Ya-Chen Tina</name>
        <uri>https://orcid.org/0000-0002-9454-4337</uri>
      </author>
      <author>
        <name>Guo, Yi</name>
      </author>
      <author>
        <name>Bian, Jiang</name>
      </author>
    </item>
    <item>
      <title>Eigenrank by committee: Von-Neumann entropy based data subset selection and failure prediction for deep learning based medical image segmentation</title>
      <link>https://escholarship.org/uc/item/126674br</link>
      <description>Manual delineation of anatomy on existing images is the basis of developing deep learning algorithms for medical image segmentation. However, manual segmentation is tedious. It is also expensive because clinician effort is necessary to ensure correctness of delineation. Consequently most algorithm development is based on a tiny fraction of the vast amount of imaging data collected at a medical center. Thus, selection of a subset of images from hospital databases for manual delineation - so that algorithms trained on such data are accurate and tolerant to variation, becomes an important challenge. We address this challenge using a novel algorithm. The proposed algorithm named 'Eigenrank by Committee' (EBC) first computes the degree of disagreement between segmentations generated by each DL model in a committee. Then, it iteratively adds to the committee, a DL model trained on cases where the disagreement is maximal. The disagreement between segmentations is quantified by the maximum...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/126674br</guid>
      <pubDate>Thu, 13 Feb 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Gaonkar, Bilwaj</name>
      </author>
      <author>
        <name>Beckett, Joel</name>
      </author>
      <author>
        <name>Attiah, Mark</name>
      </author>
      <author>
        <name>Ahn, Christine</name>
      </author>
      <author>
        <name>Edwards, Matthew</name>
      </author>
      <author>
        <name>Wilson, Bayard</name>
      </author>
      <author>
        <name>Laiwalla, Azim</name>
      </author>
      <author>
        <name>Salehi, Banafsheh</name>
      </author>
      <author>
        <name>Yoo, Bryan</name>
      </author>
      <author>
        <name>Bui, Alex AT</name>
        <uri>https://orcid.org/0000-0002-4702-1373</uri>
      </author>
      <author>
        <name>Macyszyn, Luke</name>
        <uri>https://orcid.org/0000-0002-3706-2796</uri>
      </author>
    </item>
    <item>
      <title>PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging</title>
      <link>https://escholarship.org/uc/item/93x873j3</link>
      <description>Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Design, Setting, and Participants: This post hoc, retrospective cross-sectional study included 182 patients from 4 prospective studies conducted from September 15, 2016, to September 27, 2021. All patients had recurrent prostate cancer after radical prostatectomy (RP), definitive radiotherapy (dRT), or salvage radiotherapy (SRT). Analysis was performed from January 2023 to July 2024.
Exposures: Patients included had increasing prostate-specific antigen (PSA) levels greater than 1.0 ng/mL (after RP and...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/93x873j3</guid>
      <pubDate>Wed, 12 Feb 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Holzgreve, Adrien</name>
        <uri>https://orcid.org/0000-0002-9566-8438</uri>
      </author>
      <author>
        <name>Armstrong, Wesley R</name>
      </author>
      <author>
        <name>Clark, Kevyn J</name>
      </author>
      <author>
        <name>Benz, Matthias R</name>
      </author>
      <author>
        <name>Smith, Clayton P</name>
      </author>
      <author>
        <name>Djaileb, Loïc</name>
      </author>
      <author>
        <name>Gafita, Andrei</name>
      </author>
      <author>
        <name>Thin, Pan</name>
      </author>
      <author>
        <name>Nickols, Nicholas G</name>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
      <author>
        <name>Rettig, Matthew B</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Reiter, Robert E</name>
      </author>
      <author>
        <name>Czernin, Johannes</name>
      </author>
      <author>
        <name>Calais, Jeremie</name>
        <uri>https://orcid.org/0000-0002-8839-4379</uri>
      </author>
    </item>
    <item>
      <title>Small pretreatment lesion size and high sphericity as favorable prognostic factors after laser interstitial thermal therapy in brain metastases.</title>
      <link>https://escholarship.org/uc/item/24j2v77k</link>
      <description>OBJECTIVE: The objective of this study was to identify baseline clinical and radiological characteristics of brain metastases (BMs) associated with a higher probability of lesion-specific progression-free survival (PFS-L) after laser interstitial thermal therapy (LITT).
METHODS: A total of 47 lesions in 42 patients with BMs treated with LITT were retrospectively examined, including newly diagnosed BM, suspected recurrent BM, and suspected radiation necrosis. The association of baseline clinical and radiological features with PFS-L was assessed using survival analyses. Radiological features included lesion size measurements, diffusion and perfusion metrics, and sphericity, which is a radiomic feature ranging from 1 (perfect sphere) to 0.
RESULTS: The probability of PFS-L for the entire cohort was 88.0% at 3 months, 70.6% at 6 months, 67.4% at 1 and 2 years, and 62.2% at 3 years. For lesions progressing after LITT (n = 13), the median time to progression was 3.9 months, and most...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/24j2v77k</guid>
      <pubDate>Wed, 5 Feb 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Sanvito, Francesco</name>
        <uri>https://orcid.org/0000-0003-3379-9958</uri>
      </author>
      <author>
        <name>Telesca, Donatello</name>
      </author>
      <author>
        <name>Cho, Nicholas S</name>
      </author>
      <author>
        <name>Sayari, Jessica T</name>
      </author>
      <author>
        <name>Nagaraj, Raksha</name>
      </author>
      <author>
        <name>Raymond, Catalina</name>
      </author>
      <author>
        <name>Rana, Shivam</name>
      </author>
      <author>
        <name>Patel, Kunal</name>
      </author>
      <author>
        <name>Mozaffari, Khashayar</name>
      </author>
      <author>
        <name>Unterberger, Ansley A</name>
      </author>
      <author>
        <name>Khanlou, Negar</name>
      </author>
      <author>
        <name>Magaki, Shino</name>
        <uri>https://orcid.org/0000-0003-0433-5759</uri>
      </author>
      <author>
        <name>Pouratian, Nader</name>
      </author>
      <author>
        <name>Everson, Richard G</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Yang, Isaac</name>
      </author>
      <author>
        <name>Kim, Won</name>
        <uri>https://orcid.org/0000-0003-3423-3825</uri>
      </author>
      <author>
        <name>Ellingson, Benjamin M</name>
      </author>
    </item>
    <item>
      <title>Patient-reported quality of life and adherence outcomes after integrating exclusive liquid meal replacement in patients with head and neck cancer undergoing chemoradiation: results from a phase II study</title>
      <link>https://escholarship.org/uc/item/91n0q0pj</link>
      <description>Objectives: Preventing malnutrition during chemoradiation (CRT) for head and neck cancer is critical maximizing quality of life (QOL). We sought to assess patient-reported QOL outcomes after integrating exclusive liquid meal replacement with Soylent, a novel meal replacement agent, in patients with head and neck cancer undergoing CRT.
Methods: Patients undergoing definitive or adjuvant concurrent CRT for locally advanced head and neck cancer enrolled on our single-institution, prospective phase II protocol evaluating nutritional replacement with Soylent. Patients who reached 5% body weight loss during CRT were transitioned to Soylent meal replacement for all nutritional needs. Patients who reached 10% body weight loss were recommended for gastrostomy tube (G-tube) placement. UW-QOL and FACT-H&amp;amp;N questionnaires assessed patient-reported QOL prior to the receipt of CRT and following conclusion of CRT. Paired t-test or Wilcoxon signed-rank test were performed to assess for differences...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/91n0q0pj</guid>
      <pubDate>Fri, 31 Jan 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Valle, Luca F</name>
        <uri>https://orcid.org/0000-0002-5781-4174</uri>
      </author>
      <author>
        <name>Chu, Fang-I</name>
      </author>
      <author>
        <name>Wang, Xiaoyan</name>
      </author>
      <author>
        <name>Erman, Andrew</name>
      </author>
      <author>
        <name>Hernandez, Jackie</name>
      </author>
      <author>
        <name>Kaoh, Elizabeth</name>
      </author>
      <author>
        <name>Edgar, Nicolas</name>
      </author>
      <author>
        <name>Raldow, Ann C</name>
      </author>
      <author>
        <name>Wong, Deborah J</name>
      </author>
      <author>
        <name>Steinberg, Michael L</name>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
      <author>
        <name>Chin, Robert K</name>
      </author>
      <author>
        <name>Hegde, John V</name>
      </author>
    </item>
    <item>
      <title>Necessity and impact of specialization of large foundation model for medical segmentation tasks</title>
      <link>https://escholarship.org/uc/item/7tj289fp</link>
      <description>BACKGROUND: Large foundation models, such as the Segment Anything Model (SAM), have shown remarkable performance in image segmentation tasks. However, the optimal approach to achieve true utility of these models for domain-specific applications, such as medical image segmentation, remains an open question. Recent studies have released a medical version of the foundation model MedSAM by training on vast medical data, who promised SOTA medical segmentation. Independent community inspection and dissection is needed.
PURPOSE: Foundation models are developed for general purposes. On the other hand, stable delivery of reliable performance is key to clinical utility. This study aims at elucidating the potential advantage and limitations of landing the foundation models in clinical use by assessing the performance of off-the-shelf medical foundation model MedSAM for the segmentation of anatomical structures in pelvic MR images. We also explore the simple remedies by evaluating the dependency...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7tj289fp</guid>
      <pubDate>Thu, 16 Jan 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Nguyen, Eric</name>
      </author>
      <author>
        <name>Liu, Hengjie</name>
        <uri>https://orcid.org/0000-0001-5890-2291</uri>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
    </item>
    <item>
      <title>Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.</title>
      <link>https://escholarship.org/uc/item/0g72g9bm</link>
      <description>Glioblastoma is immunologically cold and resistant to single-agent immune-checkpoint inhibitors (ICI). Our previous study of neoadjuvant pembrolizumab in surgically-accessible recurrent glioblastoma identified a molecular signature of response to ICI and suggested that neoadjuvant pembrolizumab may improve survival. To increase the power of this observation, we enrolled an additional 25 patients with a primary endpoint of evaluating the cell cycle gene signature associated with neoadjuvant pembrolizumab and performed bulk-RNA seq on resected tumor tissue (NCT02852655). Neoadjuvant pembrolizumab was associated with suppression of cell cycle/cancer proliferation genes and upregulation of T-cell/interferon-related gene expression. This signature was unique to patients treated with neoadjuvant pembrolizumab and was an independent positive risk factor for survival. Our results demonstrate a clear pharmacodynamic effect of anti-PD1 therapy in glioblastoma and identify pathways that...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0g72g9bm</guid>
      <pubDate>Thu, 16 Jan 2025 00:00:00 +0000</pubDate>
      <author>
        <name>McFaline-Figueroa, J</name>
      </author>
      <author>
        <name>Sun, Lu</name>
      </author>
      <author>
        <name>Youssef, Gilbert</name>
      </author>
      <author>
        <name>Huang, Raymond</name>
      </author>
      <author>
        <name>Li, Gang</name>
      </author>
      <author>
        <name>Kim, Jiyoon</name>
      </author>
      <author>
        <name>Lee, Eudocia</name>
      </author>
      <author>
        <name>Nayak, Lakshmi</name>
      </author>
      <author>
        <name>Chukwueke, Ugonma</name>
      </author>
      <author>
        <name>Beroukhim, Rameen</name>
      </author>
      <author>
        <name>Batchelor, Tracy</name>
      </author>
      <author>
        <name>Chiocca, E</name>
      </author>
      <author>
        <name>Everson, Richard</name>
      </author>
      <author>
        <name>Doherty, Lisa</name>
      </author>
      <author>
        <name>Stefanik, Jennifer</name>
      </author>
      <author>
        <name>Partridge, Kathryn</name>
      </author>
      <author>
        <name>Spearman, Amanda</name>
      </author>
      <author>
        <name>Myers, Alexa</name>
      </author>
      <author>
        <name>Westergaard, Catharina</name>
      </author>
      <author>
        <name>Russ, Alyssa</name>
      </author>
      <author>
        <name>Lavallee, Maria</name>
      </author>
      <author>
        <name>Smokovich, Anna</name>
      </author>
      <author>
        <name>LaForest-Roys, Corey</name>
      </author>
      <author>
        <name>Garcia Fox, Rachel</name>
      </author>
      <author>
        <name>McCluskey, Christine</name>
      </author>
      <author>
        <name>Bi, Wenya</name>
      </author>
      <author>
        <name>Arnaout, Omar</name>
      </author>
      <author>
        <name>Peruzzi, PierPaolo</name>
      </author>
      <author>
        <name>Cosgrove, G</name>
      </author>
      <author>
        <name>Ligon, Keith</name>
      </author>
      <author>
        <name>Arrillaga-Romany, Isabel</name>
      </author>
      <author>
        <name>Clarke, Jennifer</name>
      </author>
      <author>
        <name>Reardon, David</name>
      </author>
      <author>
        <name>Cloughesy, Timothy</name>
      </author>
      <author>
        <name>Prins, Robert</name>
      </author>
      <author>
        <name>Wen, Patrick</name>
      </author>
    </item>
    <item>
      <title>Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma</title>
      <link>https://escholarship.org/uc/item/2cz09554</link>
      <description>Treatment of the tumor and dural margin with surgery and sometimes radiation are cornerstones of therapy for meningioma. Molecular classifications have provided insights into the biology of disease; however, response to treatment remains heterogeneous. In this study, we used retrospective data on 2,824 meningiomas, including molecular data on 1,686 tumors and 100 prospective meningiomas, from the RTOG-0539 phase 2 trial to define molecular biomarkers of treatment response. Using propensity score matching, we found that gross tumor resection was associated with longer progression-free survival (PFS) across all molecular groups and longer overall survival in proliferative meningiomas. Dural margin treatment (Simpson grade 1/2) prolonged PFS compared to no treatment (Simpson grade 3). Molecular group classification predicted response to radiotherapy, including in the RTOG-0539 cohort. We subsequently developed a molecular model to predict response to radiotherapy that discriminates...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2cz09554</guid>
      <pubDate>Mon, 6 Jan 2025 00:00:00 +0000</pubDate>
      <author>
        <name>Wang, Justin Z</name>
      </author>
      <author>
        <name>Patil, Vikas</name>
      </author>
      <author>
        <name>Landry, Alexander P</name>
      </author>
      <author>
        <name>Gui, Chloe</name>
      </author>
      <author>
        <name>Ajisebutu, Andrew</name>
      </author>
      <author>
        <name>Liu, Jeff</name>
      </author>
      <author>
        <name>Saarela, Olli</name>
      </author>
      <author>
        <name>Pugh, Stephanie L</name>
      </author>
      <author>
        <name>Won, Minhee</name>
      </author>
      <author>
        <name>Patel, Zeel</name>
      </author>
      <author>
        <name>Yakubov, Rebeca</name>
      </author>
      <author>
        <name>Kaloti, Ramneet</name>
      </author>
      <author>
        <name>Wilson, Christopher</name>
      </author>
      <author>
        <name>Cohen-Gadol, Aaron</name>
      </author>
      <author>
        <name>Zaazoue, Mohamed A</name>
      </author>
      <author>
        <name>Tabatabai, Ghazaleh</name>
      </author>
      <author>
        <name>Tatagiba, Marcos</name>
      </author>
      <author>
        <name>Behling, Felix</name>
      </author>
      <author>
        <name>Almiron Bonnin, Damian A</name>
      </author>
      <author>
        <name>Holland, Eric C</name>
      </author>
      <author>
        <name>Kruser, Tim J</name>
      </author>
      <author>
        <name>Barnholtz-Sloan, Jill S</name>
      </author>
      <author>
        <name>Sloan, Andrew E</name>
      </author>
      <author>
        <name>Horbinski, Craig</name>
      </author>
      <author>
        <name>Chotai, Silky</name>
      </author>
      <author>
        <name>Chambless, Lola B</name>
      </author>
      <author>
        <name>Gao, Andrew</name>
      </author>
      <author>
        <name>Rebchuk, Alexander D</name>
      </author>
      <author>
        <name>Makarenko, Serge</name>
      </author>
      <author>
        <name>Yip, Stephen</name>
      </author>
      <author>
        <name>Sahm, Felix</name>
      </author>
      <author>
        <name>Maas, Sybren LN</name>
      </author>
      <author>
        <name>Tsang, Derek S</name>
      </author>
      <author>
        <name>Rogers, C Leland</name>
      </author>
      <author>
        <name>Aldape, Kenneth</name>
      </author>
      <author>
        <name>Nassiri, Farshad</name>
      </author>
      <author>
        <name>Zadeh, Gelareh</name>
      </author>
    </item>
    <item>
      <title>Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer</title>
      <link>https://escholarship.org/uc/item/9bt5w5vj</link>
      <description>BACKGROUND AND OBJECTIVE: We characterized tumor prostate-specific membrane antigen (PSMA) levels as a reflection of cancer biology and treatment sensitivities for treatment-naïve prostate cancer.
METHODS: We first correlated PSMA positron emission tomography (PET) maximum standardized uptake values (SUVmax) in primary prostate cancer with tumor FOLH1 (PSMA RNA abundance) to establish RNA as a proxy (n&amp;nbsp;=&amp;nbsp;55). We then discovered and validated molecular pathways associated with PSMA RNA levels in two large primary tumor cohorts. We validated those associations in independent cohorts (18 total; 5684 tumor samples) to characterize the pathways and treatment responses associated with PSMA.
KEY FINDINGS AND LIMITATIONS: PSMA RNA abundance correlates moderately with SUVmax (ρ&amp;nbsp;=&amp;nbsp;0.41). In independent cohorts, androgen receptor signaling is more active in tumors with high PSMA. Accordingly, patients with high PSMA tumors experienced longer cancer-specific survival when...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9bt5w5vj</guid>
      <pubDate>Sat, 28 Dec 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Weiner, Adam B</name>
      </author>
      <author>
        <name>Agrawal, Raag</name>
        <uri>https://orcid.org/0000-0001-8222-3117</uri>
      </author>
      <author>
        <name>Wang, Nicholas K</name>
        <uri>https://orcid.org/0000-0003-1043-3072</uri>
      </author>
      <author>
        <name>Sonni, Ida</name>
      </author>
      <author>
        <name>Li, Eric V</name>
      </author>
      <author>
        <name>Arbet, Jaron</name>
      </author>
      <author>
        <name>Zhang, JJH</name>
      </author>
      <author>
        <name>Proudfoot, James A</name>
      </author>
      <author>
        <name>Hong, Boon Hao</name>
      </author>
      <author>
        <name>Davicioni, Elai</name>
      </author>
      <author>
        <name>Kane, Nathanael</name>
      </author>
      <author>
        <name>Valle, Luca F</name>
        <uri>https://orcid.org/0000-0002-5781-4174</uri>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
      <author>
        <name>Dal Pra, Alan</name>
      </author>
      <author>
        <name>Ghadjar, Pirus</name>
      </author>
      <author>
        <name>Sweeney, Christopher J</name>
      </author>
      <author>
        <name>Nickols, Nicholas G</name>
      </author>
      <author>
        <name>Karnes, R Jeffrey</name>
      </author>
      <author>
        <name>Shen, John</name>
      </author>
      <author>
        <name>Rettig, Matthew B</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Czernin, Johannes</name>
      </author>
      <author>
        <name>Ross, Ashely E</name>
      </author>
      <author>
        <name>Chua, Melvin Lee Kiang</name>
      </author>
      <author>
        <name>Schaeffer, Edward M</name>
      </author>
      <author>
        <name>Calais, Jeremie</name>
        <uri>https://orcid.org/0000-0002-8839-4379</uri>
      </author>
      <author>
        <name>Boutros, Paul C</name>
        <uri>https://orcid.org/0000-0003-0553-7520</uri>
      </author>
      <author>
        <name>Reiter, Robert E</name>
      </author>
    </item>
    <item>
      <title>A quantitative CBCT pipeline based on 2D antiscatter grid and grid‐based scatter sampling for image‐guided radiation therapy</title>
      <link>https://escholarship.org/uc/item/0pz035f9</link>
      <description>BACKGROUND: Quantitative accuracy is critical for expanding the role of cone beam CT (CBCT) imaging from target localization to quantitative treatment monitoring and plan adaptations in radiation therapy. Despite advances in CBCT image quality improvement methods, quantitative accuracy gap between CBCT and multi-detector CT (MDCT) remains.
PURPOSE: In this work, a physics-driven approach was investigated that combined robust scatter rejection, raw data correction and iterative image reconstruction to further improve CBCT image quality and quantitative accuracy, referred to as quantitative CBCT (qCBCT).
METHODS: QCBCT approach includes tungsten 2D antiscatter grid hardware, residual scatter correction with grid-based scatter sampling, image lag, and beam hardening correction for offset detector geometry linac-mounted CBCT. Images were reconstructed with iterative image reconstruction to reduce image noise. qCBCT was evaluated using a variety of phantoms to investigate the effect...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0pz035f9</guid>
      <pubDate>Wed, 11 Dec 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Bayat, Farhang</name>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
      <author>
        <name>Miften, Moyed</name>
      </author>
      <author>
        <name>Altunbas, Cem</name>
      </author>
    </item>
    <item>
      <title>MRI and pathology comparisons in Rasmussen’s encephalitis: a multi-institutional examination of hemispherotomy outcomes relative to imaging and histological severity</title>
      <link>https://escholarship.org/uc/item/02d5b2bc</link>
      <description>PurposeRasmussen encephalitis (RE) is a very rare chronic neurological disorder of unilateral inflammation of the cerebral cortex. Hemispherotomy provides the best chance at achieving seizure freedom in RE patients, but with significant risks and variable long-term outcomes. The goal of this study is to utilize our multicenter pediatric cohort to characterize if differences in pathology and/or imaging characterization of RE may provide a window into post-operative seizure outcomes, which in turn could guide decision-making for parents and healthcare providers.MethodsThis multi-institutional retrospective review of medical record, imaging, and pathology samples was approved by each individual institution’s review board. Data was collected from all known pediatric cases of peri-insular functional hemispherotomy from the earliest available electronic medical records. Mean follow-up time was 4.9&amp;nbsp;years. Clinical outcomes were measured by last follow-up visit using both Engel and...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/02d5b2bc</guid>
      <pubDate>Sat, 7 Dec 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Doherty, Alexander</name>
      </author>
      <author>
        <name>Knudson, Kathleen</name>
      </author>
      <author>
        <name>Fuller, Christine</name>
      </author>
      <author>
        <name>Leach, James L</name>
      </author>
      <author>
        <name>Wang, Anthony C</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
      <author>
        <name>Marupudi, Neena</name>
      </author>
      <author>
        <name>Han, Rowland H</name>
      </author>
      <author>
        <name>Tomko, Stuart</name>
      </author>
      <author>
        <name>Ojemann, Jeff</name>
      </author>
      <author>
        <name>Smyth, Matthew D</name>
      </author>
      <author>
        <name>Mangano, Francesco</name>
      </author>
      <author>
        <name>Skoch, Jesse</name>
      </author>
    </item>
    <item>
      <title>Simplified methods for variance estimation in microbiome abundance count data analysis</title>
      <link>https://escholarship.org/uc/item/1z51v88r</link>
      <description>The complex nature of microbiome data has made the differential abundance analysis challenging. Microbiome abundance counts are often skewed to the right and heteroscedastic (also known as overdispersion), potentially leading to incorrect inferences if not properly addressed. In this paper, we propose a simple yet effective framework to tackle the challenges by integrating Poisson (log-linear) regression with standard error estimation through the Bootstrap method and Sandwich robust estimation. Such standard error estimates are accurate and yield satisfactory inference even if the distributional assumption or the variance structure is incorrect. Our approach is validated through extensive simulation studies, demonstrating its effectiveness in addressing overdispersion and improving inference accuracy. Additionally, we apply our approach to two real datasets collected from the human gut and vagina, respectively, demonstrating the wide applicability of our methods. The results highlight...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1z51v88r</guid>
      <pubDate>Thu, 5 Dec 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Shi, Yiming</name>
      </author>
      <author>
        <name>Liu, Lili</name>
      </author>
      <author>
        <name>Chen, Jun</name>
      </author>
      <author>
        <name>Wylie, Kristine M</name>
      </author>
      <author>
        <name>Wylie, Todd N</name>
      </author>
      <author>
        <name>Stout, Molly J</name>
      </author>
      <author>
        <name>Wang, Chan</name>
      </author>
      <author>
        <name>Zhang, Haixiang</name>
      </author>
      <author>
        <name>Shih, Ya-Chen T</name>
        <uri>https://orcid.org/0000-0002-9454-4337</uri>
      </author>
      <author>
        <name>Xu, Xiaoyi</name>
      </author>
      <author>
        <name>Zhang, Ai</name>
      </author>
      <author>
        <name>Park, Sung Hee</name>
      </author>
      <author>
        <name>Jiang, Hongmei</name>
      </author>
      <author>
        <name>Liu, Lei</name>
      </author>
    </item>
    <item>
      <title>Costs and Access Barriers to Ondansetron in the US</title>
      <link>https://escholarship.org/uc/item/6cf0g7bm</link>
      <description>&lt;p&gt;This cross-sectional study compares the use of management tools and plan-level total costs for oral ondansetron between Part D independent prescription drug plans and Medicare Advantage prescription drug plans.&lt;/p&gt;</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6cf0g7bm</guid>
      <pubDate>Wed, 4 Dec 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Jiang, Changchuan</name>
      </author>
      <author>
        <name>Yabroff, K Robin</name>
      </author>
      <author>
        <name>Nipp, Ryan D</name>
      </author>
      <author>
        <name>Han, Xuesong</name>
      </author>
      <author>
        <name>Hu, Xin</name>
      </author>
      <author>
        <name>Liao, Joshua M</name>
      </author>
      <author>
        <name>Shih, Ya-Chen Tina</name>
        <uri>https://orcid.org/0000-0002-9454-4337</uri>
      </author>
    </item>
    <item>
      <title>Symptom-associated alterations in functional connectivity in primary and secondary provoked vestibulodynia</title>
      <link>https://escholarship.org/uc/item/1sm8c0j0</link>
      <description>ABSTRACT: Primary provoked vestibulodynia (PVD) is marked by the onset of symptoms at first provoking vulvar contact, whereas secondary PVD refers to symptom onset after some period of painless vulvar contact. Different pathophysiological processes are believed to be involved in the development and maintenance of primary PVD and secondary PVD. The primary aim of this study was to test the hypotheses that the resting state functional connectivity of the brain and brain stem regions differs between these subtypes. Deep clinical phenotyping and resting state brain imaging were obtained in a large sample of a women with primary PVD (n = 46), those with secondary PVD (n = 68), and healthy control women (n = 94). The general linear model was used to test for differences in region-to-region resting state functional connectivity and psychosocial and symptom assessments. Direct statistical comparisons by onset type indicated that women with secondary PVD have increased dorsal attention-somatomotor...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1sm8c0j0</guid>
      <pubDate>Fri, 22 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Oughourlian, Talia C</name>
        <uri>https://orcid.org/0000-0001-8133-2928</uri>
      </author>
      <author>
        <name>Tun, Guistinna</name>
      </author>
      <author>
        <name>Antony, Kevin M</name>
      </author>
      <author>
        <name>Gupta, Arpana</name>
      </author>
      <author>
        <name>Mays, Vickie M</name>
      </author>
      <author>
        <name>Mayer, Emeran A</name>
        <uri>https://orcid.org/0000-0003-3923-3349</uri>
      </author>
      <author>
        <name>Rapkin, Andrea J</name>
      </author>
      <author>
        <name>Labus, Jennifer S</name>
        <uri>https://orcid.org/0000-0002-6634-2551</uri>
      </author>
    </item>
    <item>
      <title>Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance</title>
      <link>https://escholarship.org/uc/item/78r0w0zr</link>
      <description>&lt;b&gt;&lt;i&gt;Significance:&lt;/i&gt;&lt;/b&gt; Glioblastomas (GBMs) are among the most lethal tumors despite the almost exclusive localization to the brain. This is largely due to therapeutic resistance. Radiation and chemotherapy significantly increase the survival for GBM patients, however, GBMs always recur, and the median overall survival is just over a year. Proposed reasons for such intractable resistance to therapy are numerous and include tumor metabolism, in particular, the ability of tumor cells to reconfigure metabolic fluxes on demand (metabolic plasticity). Understanding how the hard-wired, oncogene-driven metabolic tendencies of GBMs intersect with flexible, context-induced metabolic rewiring promises to reveal novel approaches for combating therapy resistance. &lt;b&gt;&lt;i&gt;Recent Advances:&lt;/i&gt;&lt;/b&gt; Personalized genome-scale metabolic flux models have recently provided evidence that metabolic flexibility promotes radiation resistance in cancer and identified tumor redox metabolism as a major...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/78r0w0zr</guid>
      <pubDate>Tue, 19 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Bailleul, Justine</name>
        <uri>https://orcid.org/0000-0002-3974-1928</uri>
      </author>
      <author>
        <name>Vlashi, Erina</name>
      </author>
    </item>
    <item>
      <title>The Association of Organizational Readiness With Lung Cancer Screening Utilization</title>
      <link>https://escholarship.org/uc/item/7k0015px</link>
      <description>INTRODUCTION: Lung cancer screening is widely underutilized. Organizational factors, such as readiness for change and belief in the value of change (change valence), may contribute to underutilization. The aim of this study was to evaluate the association between healthcare organizations' preparedness and lung cancer screening utilization.
METHODS: Investigators cross-sectionally surveyed clinicians, staff, and leaders at10 Veterans Affairs from November 2018 to February 2021 to assess organizational readiness to implement change. In 2022, investigators used simple and multivariable linear regression to evaluate the associations between facility-level organizational readiness to implement change and change valence with lung cancer screening utilization. Organizational readiness to implement change and change valence were calculated from individual surveys. The primary outcome was the proportion of eligible Veterans screened using low-dose computed tomography. Secondary analyses...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7k0015px</guid>
      <pubDate>Wed, 13 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Lewis, Jennifer A</name>
      </author>
      <author>
        <name>Samuels, Lauren R</name>
      </author>
      <author>
        <name>Weems, Jacy</name>
      </author>
      <author>
        <name>Park, Daniel</name>
      </author>
      <author>
        <name>Winter, Robert</name>
      </author>
      <author>
        <name>Lindsell, Christopher J</name>
      </author>
      <author>
        <name>Callaway-Lane, Carol</name>
      </author>
      <author>
        <name>Audet, Carolyn</name>
      </author>
      <author>
        <name>Slatore, Christopher G</name>
      </author>
      <author>
        <name>Wiener, Renda Soylemez</name>
      </author>
      <author>
        <name>Dittus, Robert S</name>
      </author>
      <author>
        <name>Kripalani, Sunil</name>
      </author>
      <author>
        <name>Yankelevitz, David F</name>
      </author>
      <author>
        <name>Henschke, Claudia I</name>
      </author>
      <author>
        <name>Moghanaki, Drew</name>
        <uri>https://orcid.org/0000-0002-5129-2184</uri>
      </author>
      <author>
        <name>Matheny, Michael E</name>
      </author>
      <author>
        <name>Vogus, Timothy J</name>
      </author>
      <author>
        <name>Roumie, Christianne L</name>
      </author>
      <author>
        <name>Spalluto, Lucy B</name>
      </author>
    </item>
    <item>
      <title>Nicotinamide Adenine Dinucleotide Phosphate Oxidase Promotes Glioblastoma Radiation Resistance in a Phosphate and Tensin Homolog-Dependent Manner</title>
      <link>https://escholarship.org/uc/item/0pc542zt</link>
      <description>&lt;b&gt;&lt;i&gt;Aims:&lt;/i&gt;&lt;/b&gt; The goal of this study was to determine whether nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX)-produced reactive oxygen species (ROS) enhance brain tumor growth of glioblastoma (GBM) under hypoxic conditions and during radiation treatment. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Exogenous ROS promoted brain tumor growth in gliomasphere cultures that expressed functional phosphate and tensin homolog (PTEN), but not in tumors that were PTEN deficient. Hypoxia induced the production of endogenous cytoplasmic ROS and tumor cell growth &lt;i&gt;via&lt;/i&gt; activation of NOX. NOX activation resulted in oxidation of PTEN and downstream protein kinase B (Akt) activation. Radiation also promoted ROS production &lt;i&gt;via&lt;/i&gt; NOX, which, in turn, resulted in cellular protection that could be abrogated by knockdown of the key NOX component, p22. Knockdown of p22 also inhibited tumor growth and enhanced the efficacy of radiation in PTEN-expressing GBM cells. &lt;b&gt;&lt;i&gt;Innovation:&lt;/i&gt;&lt;/b&gt;...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0pc542zt</guid>
      <pubDate>Wed, 13 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Ludwig, Kirsten</name>
      </author>
      <author>
        <name>Le Belle, Janel E</name>
      </author>
      <author>
        <name>Muthukrishnan, Sree Deepthi</name>
      </author>
      <author>
        <name>Sperry, Jantzen</name>
      </author>
      <author>
        <name>Condro, Michael</name>
        <uri>https://orcid.org/0000-0001-9591-4814</uri>
      </author>
      <author>
        <name>Vlashi, Erina</name>
      </author>
      <author>
        <name>Pajonk, Frank</name>
      </author>
      <author>
        <name>Kornblum, Harley I</name>
      </author>
    </item>
    <item>
      <title>Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer</title>
      <link>https://escholarship.org/uc/item/39c5p2tm</link>
      <description>PURPOSE: Oligorecurrent prostate cancer has historically been treated with indefinite androgen deprivation therapy (ADT), although many patients and providers opt to defer this treatment at the time of recurrence given quality-of-life and/or comorbidity considerations. Recently, metastasis-directed therapy (MDT) has emerged as a potential intermediary between surveillance and immediate continuous ADT. Simultaneously, advanced systemic therapy in addition to ADT has also been shown to improve survival in metastatic hormone-sensitive disease. This study aimed to compare the cost-effectiveness of treating oligorecurrent patients with upfront MDT before standard-of-care systemic therapy.
METHODS AND MATERIALS: A Markov-based cost-effectiveness analysis was constructed comparing 3 strategies: (1) upfront MDT → salvage abiraterone acetate plus prednisone (AAP) + ADT → salvage docetaxel + ADT; (2) upfront AAP + ADT → salvage docetaxel + ADT; and (3) upfront docetaxel + ADT → salvage...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/39c5p2tm</guid>
      <pubDate>Fri, 8 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Parikh, Neil R</name>
      </author>
      <author>
        <name>Chang, Eric M</name>
      </author>
      <author>
        <name>Nickols, Nicholas G</name>
      </author>
      <author>
        <name>Rettig, Matthew B</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Raldow, Ann C</name>
      </author>
      <author>
        <name>Steinberg, Michael L</name>
      </author>
      <author>
        <name>Koontz, Bridget F</name>
      </author>
      <author>
        <name>Vapiwala, Neha</name>
      </author>
      <author>
        <name>Deville, Curtiland</name>
      </author>
      <author>
        <name>Feng, Felix Y</name>
      </author>
      <author>
        <name>Spratt, Daniel E</name>
      </author>
      <author>
        <name>Reiter, Robert E</name>
      </author>
      <author>
        <name>Phillips, Ryan</name>
      </author>
      <author>
        <name>Ost, Piet</name>
      </author>
      <author>
        <name>Tran, Phuoc T</name>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
    </item>
    <item>
      <title>SARS-CoV-2 infection exacerbates the cellular pathology of Parkinson’s disease in human dopaminergic neurons and a mouse model</title>
      <link>https://escholarship.org/uc/item/9pq6x49v</link>
      <description>While an association between Parkinson's disease (PD) and viral infections has been recognized, the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on PD progression remains unclear. Here, we demonstrate that SARS-CoV-2 infection heightens the risk of PD using human embryonic stem cell (hESC)-derived dopaminergic (DA) neurons and a human angiotensin-converting enzyme 2 (hACE2) transgenic (Tg) mouse model. Our findings reveal that SARS-CoV-2 infection exacerbates PD susceptibility and cellular toxicity in DA neurons pre-treated with human preformed fibrils (hPFFs). Additionally, nasally delivered SARS-CoV-2 infects DA neurons in hACE2 Tg mice, aggravating the damage initiated by hPFFs. Mice infected with SARS-CoV-2 display persisting neuroinflammation even after the virus is no longer detectable in the brain. A comprehensive analysis suggests that the inflammatory response mediated by astrocytes and microglia could contribute to increased PD susceptibility...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9pq6x49v</guid>
      <pubDate>Thu, 7 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Lee, Bina</name>
      </author>
      <author>
        <name>Choi, Ha Nyeoung</name>
      </author>
      <author>
        <name>Hyun, Young</name>
      </author>
      <author>
        <name>Ko, Myungjun</name>
      </author>
      <author>
        <name>Seong, Hye Min</name>
      </author>
      <author>
        <name>Jo, Min Gi</name>
      </author>
      <author>
        <name>Kim, Seon-Hee</name>
      </author>
      <author>
        <name>Song, Chieun</name>
      </author>
      <author>
        <name>Yoon, Subeen</name>
      </author>
      <author>
        <name>Choi, Jiwoo</name>
      </author>
      <author>
        <name>Kim, Jeong Hee</name>
      </author>
      <author>
        <name>Kim, Minkyeong</name>
      </author>
      <author>
        <name>Lee, Min Young</name>
      </author>
      <author>
        <name>Park, Sang Won</name>
      </author>
      <author>
        <name>Kim, Hye Jung</name>
      </author>
      <author>
        <name>Kim, Seong Jae</name>
      </author>
      <author>
        <name>Moon, Sik</name>
      </author>
      <author>
        <name>Lee, Sun</name>
      </author>
      <author>
        <name>Park, Jae-Hoon</name>
      </author>
      <author>
        <name>Yeo, Seung-Geun</name>
      </author>
      <author>
        <name>Everson, Richard G</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Kim, Young Jin</name>
      </author>
      <author>
        <name>Hong, Kyung-Wook</name>
      </author>
      <author>
        <name>Roh, In-Soon</name>
      </author>
      <author>
        <name>Lyoo, Kwang-Soo</name>
      </author>
      <author>
        <name>Kim, Yong Jun</name>
      </author>
      <author>
        <name>Yun, Seung Pil</name>
      </author>
    </item>
    <item>
      <title>Hospital-level variation in hospitalization costs for spinal fusion in the United States</title>
      <link>https://escholarship.org/uc/item/8b809314</link>
      <description>BACKGROUND: With a growing emphasis on value of care, understanding factors associated with rising healthcare costs is increasingly important. In this national study, we evaluated the degree of center-level variation in the cost of spinal fusion.
METHODS: All adults undergoing elective spinal fusion were identified in the 2016 to 2020 National Inpatient Sample. Multilevel mixed-effect models were used to rank hospitals based on risk-adjusted costs. The interclass coefficient (ICC) was utilized to tabulate the amount of variation attributable to hospital-level characteristics. The association of high cost-hospital (HCH) status with in-hospital mortality, perioperative complications, and overall resource utilization was analyzed. Predictors of increased costs were secondarily explored.
RESULTS: An estimated 1,541,740 patients underwent spinal fusion, and HCH performed an average of 9.5% of annual cases. HCH were more likely to be small (36.8 vs 30.5%, p&amp;lt;0.001), rural (10.1 vs...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8b809314</guid>
      <pubDate>Thu, 7 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Curry, Joanna</name>
      </author>
      <author>
        <name>Cho, Nam Yong</name>
      </author>
      <author>
        <name>Nesbit, Shannon</name>
      </author>
      <author>
        <name>Kim, Shineui</name>
      </author>
      <author>
        <name>Ali, Konmal</name>
      </author>
      <author>
        <name>Gudapati, Varun</name>
      </author>
      <author>
        <name>Everson, Richard</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Benharash, Peyman</name>
      </author>
    </item>
    <item>
      <title>Structural connections of the centromedian nucleus of thalamus and their relevance for neuromodulation in generalized drug-resistant epilepsy: insight from a tractography study</title>
      <link>https://escholarship.org/uc/item/3r6364dc</link>
      <description>Background: Epilepsy is a widespread neurologic disorder and almost one-third of patients suffer from drug-resistant epilepsy (DRE). Neuromodulation targeting the centromediannucleus of the thalamus (CM) has been showing promising results for patients with generalized DRE who are not surgical candidates. Recently, the effect of CM- deep brain stimulation (DBS) in DRE patients was investigated in the Electrical Stimulation of Thalamus for Epilepsy of Lennox-Gastaut phenotype (ESTEL) trial, a monocentric randomized-controlled study. The same authors described a 'cold-spot' and a 'sweet-spot', which are defined as the volume of stimulation in the thalamus yielding the least and the best clinical response, respectively. However, it remains unclear which structural connections may contribute to the anti-seizure effect of the stimulation.
Objective: We investigated the differences in structural connectivity among CM, the sweet-spot and the cold-spot. Furthermore, we tried to validate...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3r6364dc</guid>
      <pubDate>Thu, 7 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Remore, Luigi G</name>
      </author>
      <author>
        <name>Rifi, Ziad</name>
      </author>
      <author>
        <name>Nariai, Hiroki</name>
        <uri>https://orcid.org/0000-0002-8318-2924</uri>
      </author>
      <author>
        <name>Eliashiv, Dawn S</name>
      </author>
      <author>
        <name>Fallah, Aria</name>
      </author>
      <author>
        <name>Edmonds, Benjamin D</name>
      </author>
      <author>
        <name>Matsumoto, Joyce H</name>
      </author>
      <author>
        <name>Salamon, Noriko</name>
        <uri>https://orcid.org/0000-0002-3520-9467</uri>
      </author>
      <author>
        <name>Tolossa, Meskerem</name>
      </author>
      <author>
        <name>Wei, Wexin</name>
      </author>
      <author>
        <name>Locatelli, Marco</name>
      </author>
      <author>
        <name>Tsolaki, Evangelia C</name>
      </author>
      <author>
        <name>Bari, Ausaf A</name>
        <uri>https://orcid.org/0000-0002-5279-5023</uri>
      </author>
    </item>
    <item>
      <title>Intraoperative discovery of a radiographically occult subependymoma obstructing the obex in a patient with a Chiari malformation – A rare case</title>
      <link>https://escholarship.org/uc/item/2bz781rk</link>
      <description>Background: Chiari (type I) malformations are typically congenital. Occasionally, however, tonsillar herniation can arise secondary to cerebrospinal fluid leakage, posterior fossa or intraventricular mass lesions, or other etiologies. We present the first-ever case of an intramedullary subependymoma at the cervicomedullary junction associated with vertebral bone abnormalities and an acquired secondary Chiari malformation.
Case Description: A 60-year-old woman presented with a 3-year history of occipital, tussive headaches. Preoperative imaging was negative for mass lesions but demonstrated a Chiari malformation. She was recommended posterior fossa decompression with tonsillar shrinkage. During surgery, an intramedullary mass was incidentally observed, obstructing the obex at the cervicomedullary junction. Histopathological analysis of the resected lesion revealed a diagnosis of subependymoma.
Conclusion: Subependymomas can sometimes present a diagnostic challenge due to their...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2bz781rk</guid>
      <pubDate>Thu, 7 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Peeters, Sophie F</name>
      </author>
      <author>
        <name>Uhr, Lauren</name>
      </author>
      <author>
        <name>Chivukula, Srinivas</name>
      </author>
      <author>
        <name>Everson, Richard</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Duong, Duc</name>
      </author>
      <author>
        <name>McBride, Duncan</name>
      </author>
      <author>
        <name>Kim, Won</name>
      </author>
      <author>
        <name>Cornford, Marcia</name>
      </author>
      <author>
        <name>Mlikotic, Anton</name>
      </author>
      <author>
        <name>Yang, Isaac</name>
      </author>
    </item>
    <item>
      <title>Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice</title>
      <link>https://escholarship.org/uc/item/1dm8z0mz</link>
      <description>PurposeFibroblast Activation Protein (FAP) is an emerging theranostic target that is highly expressed on cancer-associated fibroblasts and on certain tumor cells including sarcoma. We investigated the anti-tumor efficacy of [225Ac]Ac-FAPI-46 as monotherapy or in combination with immune checkpoint blockade (ICB) in immunocompetent murine models of sarcoma sensitive or resistant to ICB.Methods[68Ga]Ga- and [225Ac]Ac-FAPI-46 were tested in subcutaneous FAP+ FSA fibrosarcoma bearing C3H/Sed/Kam mice. The efficacy of up to three cycles of 60 kBq [225Ac]Ac-FAPI-46 was evaluated as monotherapy and in combination with an anti-PD-1 antibody. Efficacy of [225Ac]Ac-FAPI-46 and/or ICB was further compared in FAP-overexpressing FSA (FSA-F) tumors that were sensitive to ICB or rendered ICB-resistant by tumor-induction in the presence of Abatacept.Results[225Ac]Ac-FAPI-46 was well tolerated up to 3 × 60 kBq but had minimal effect on FSA tumor growth. The combination of three cycles [225Ac]Ac-FAPI-46...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1dm8z0mz</guid>
      <pubDate>Thu, 7 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Taddio, Marco F</name>
      </author>
      <author>
        <name>Doshi, Suraj</name>
      </author>
      <author>
        <name>Masri, Marwan</name>
      </author>
      <author>
        <name>Jeanjean, Pauline</name>
      </author>
      <author>
        <name>Hikmat, Firas</name>
      </author>
      <author>
        <name>Gerlach, Alana</name>
      </author>
      <author>
        <name>Nyiranshuti, Lea</name>
      </author>
      <author>
        <name>Rosser, Ethan W</name>
      </author>
      <author>
        <name>Schaue, Dorthe</name>
      </author>
      <author>
        <name>Besserer-Offroy, Elie</name>
      </author>
      <author>
        <name>Carlucci, Giuseppe</name>
      </author>
      <author>
        <name>Radu, Caius G</name>
        <uri>https://orcid.org/0000-0002-9338-5397</uri>
      </author>
      <author>
        <name>Czernin, Johannes</name>
      </author>
      <author>
        <name>Lückerath, Katharina</name>
      </author>
      <author>
        <name>Mona, Christine E</name>
      </author>
    </item>
    <item>
      <title>Ossified spinal epidermoid cyst: A systematic review and case report.</title>
      <link>https://escholarship.org/uc/item/5n0400nv</link>
      <description>BACKGROUND: Epidermoid cysts (ECs) are rare, benign lesions which comprise less than 1&amp;nbsp;% of all spinal tumors. Calcification of spinal ECs is rare, and EC ossification within the lumbar spine has never been documented. We report the only known congenital lumbar epidermoid tumor with ossification and a literature review of intradural lumbar ECs. METHODS: Studies meeting the following criteria were included: 1) EC as the primary tumor type, 2) intradural location, 3) involvement of the lumbar spinal level, and 4) primary presentation. Studies lacking individual patient data or published in a non-English language were excluded. RESULTS: A total of 172 studies were reviewed and 43 were included in analysis. Of the 83 total patients, 37 (45.1&amp;nbsp;%) were male and 45 (54.9&amp;nbsp;%) female, at an average age of 26 years. The L3 and L4 spinal levels were most frequently involved. Acquired etiology was reported in 49 (59.0&amp;nbsp;%) patients, and 24 (28.9&amp;nbsp;%) cases were congenital....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5n0400nv</guid>
      <pubDate>Sat, 2 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Hovis, Gabrielle</name>
      </author>
      <author>
        <name>Chandla, Anubhav</name>
      </author>
      <author>
        <name>Kolker, Steven</name>
      </author>
      <author>
        <name>Yang, Isaac</name>
      </author>
      <author>
        <name>Nagasawa, Daniel</name>
      </author>
    </item>
    <item>
      <title>Financial toxicity in breast cancer patients receiving regional nodal irradiation: Variation by cancer subtype.</title>
      <link>https://escholarship.org/uc/item/5c3934fm</link>
      <description>BACKGROUND: We evaluated sociodemographic and clinical predictors of financial toxicity (FT) among patients with breast cancer with higher risk clinical factors warranting regional nodal irradiation (RNI). METHODS: Among 183 participants in a clinical trial of conventional vs. hypofractionated treatment with RNI, 125 (68&amp;nbsp;%) completed a pilot survey of FT measured using the validated Economic Strain and Resilience in Cancer (ENRICh) instrument, scored from 0 (minimal) to 10 (severe) FT. Associations with predictors were evaluated using Pearson correlation coefficients and Kruskal Wallis, Mann-Whitney U, and Jonckheere-Terpstra tests. Predictors of severe FT (ENRICh≥5) were tested using multivariable logistic regression with odds ratios converted to relative risks (RR). RESULTS: Of the sample, all received RNI, 92&amp;nbsp;% chemotherapy, 67&amp;nbsp;% axillary dissection, 26&amp;nbsp;% mastectomy without reconstruction, and 32&amp;nbsp;% mastectomy with reconstruction. At a median follow...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5c3934fm</guid>
      <pubDate>Sat, 2 Nov 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Smith, Grace</name>
      </author>
      <author>
        <name>Smith, Benjamin</name>
      </author>
      <author>
        <name>Wu, Chi-Fang</name>
      </author>
      <author>
        <name>Shaitelman, Simona</name>
      </author>
      <author>
        <name>Chavez-MacGregor, Mariana</name>
      </author>
      <author>
        <name>Murthy, Rashmi</name>
      </author>
      <author>
        <name>Kaiser, Kelsey</name>
      </author>
      <author>
        <name>Ku, Kimberly</name>
      </author>
      <author>
        <name>Shi, Julia</name>
      </author>
      <author>
        <name>Shete, Sanjay</name>
      </author>
      <author>
        <name>Chen, Ying-Shiuan</name>
      </author>
      <author>
        <name>Volk, Robert</name>
      </author>
      <author>
        <name>Giordano, Sharon</name>
      </author>
      <author>
        <name>Shih, Ya-Chen</name>
      </author>
      <author>
        <name>Hoffman, Karen</name>
      </author>
    </item>
    <item>
      <title>Characteristics of ictal thalamic EEG in pediatric-onset neocortical focal epilepsy</title>
      <link>https://escholarship.org/uc/item/4sh3z1xt</link>
      <description>OBJECTIVE: To characterize ictal EEG change in the centromedian (CM) and anterior nucleus (AN) of the thalamus, using stereoelectroencephalography (SEEG) recordings.
METHODS: Forty habitual seizures were analyzed in nine patients with pediatric-onset neocortical drug-resistant epilepsy who underwent SEEG (age 2-25 y) with thalamic coverage. Both visual and quantitative analysis was used to evaluate ictal EEG signal in the cortex and thalamus. The amplitude and cortico-thalamic latencies of broadband frequencies at ictal onset were measured.
RESULTS: Visual analysis demonstrated consistent detection of ictal EEG changes in both the CM nucleus and AN nucleus with latency to thalamic ictal EEG changes of less than 400&amp;nbsp;ms in 95% of seizures, with low-voltage fast activity being the most common ictal pattern. Quantitative broadband amplitude analysis showed consistent power changes across the frequency bands, corresponding to ictal EEG onset, while while ictal EEG latency was...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4sh3z1xt</guid>
      <pubDate>Wed, 30 Oct 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Edmonds, Benjamin</name>
      </author>
      <author>
        <name>Miyakoshi, Makoto</name>
      </author>
      <author>
        <name>Remore, Luigi Gianmaria</name>
      </author>
      <author>
        <name>Ahn, Samuel</name>
      </author>
      <author>
        <name>Phillips, H Westley</name>
      </author>
      <author>
        <name>Daida, Atsuro</name>
      </author>
      <author>
        <name>Salamon, Noriko</name>
        <uri>https://orcid.org/0000-0002-3520-9467</uri>
      </author>
      <author>
        <name>Bari, Ausaf</name>
        <uri>https://orcid.org/0000-0002-5279-5023</uri>
      </author>
      <author>
        <name>Sankar, Raman</name>
      </author>
      <author>
        <name>Matsumoto, Joyce H</name>
      </author>
      <author>
        <name>Fallah, Aria</name>
      </author>
      <author>
        <name>Nariai, Hiroki</name>
        <uri>https://orcid.org/0000-0002-8318-2924</uri>
      </author>
    </item>
    <item>
      <title>Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial</title>
      <link>https://escholarship.org/uc/item/44t034s7</link>
      <description>PURPOSE: Postoperative radiation therapy (RT) is an underused standard-of-care intervention for patients with prostate cancer and recurrence/adverse pathologic features after radical prostatectomy. Although stereotactic body RT (SBRT) is a well-studied and convenient option for definitive treatment, data on the postprostatectomy setting are extremely limited. The purpose of this study was to evaluate short-term physician-scored genitourinary (GU) and gastrointestinal (GI) toxicities and patient-reported outcomes after postprostatectomy SBRT.
METHODS AND MATERIALS: The SCIMITAR trial was a phase 2, dual-center, open-label, single-arm trial that enrolled patients with postoperative prostate-specific antigen &amp;gt;0.03 ng/mL or adverse pathologic features. Coprimary endpoints were 4-year biochemical recurrence-free survival, physician-scored acute and late GU and GI toxicities by the Common Terminology Criteria for Adverse Events (version 4.03) scale, and patient-reported quality-of-life...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/44t034s7</guid>
      <pubDate>Wed, 30 Oct 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Martin, Ting</name>
      </author>
      <author>
        <name>Ballas, Leslie K</name>
      </author>
      <author>
        <name>Wilhalme, Holly</name>
        <uri>https://orcid.org/0000-0001-9908-6219</uri>
      </author>
      <author>
        <name>Sachdeva, Ankush</name>
      </author>
      <author>
        <name>Chong, Natalie</name>
      </author>
      <author>
        <name>Sharma, Sahil</name>
      </author>
      <author>
        <name>Yang, Tiffany</name>
      </author>
      <author>
        <name>Basehart, Vincent</name>
      </author>
      <author>
        <name>Reiter, Robert E</name>
      </author>
      <author>
        <name>Saigal, Christopher</name>
      </author>
      <author>
        <name>Chamie, Karim</name>
      </author>
      <author>
        <name>Litwin, Mark S</name>
      </author>
      <author>
        <name>Rettig, Matthew B</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Nickols, Nicholas G</name>
      </author>
      <author>
        <name>Yoon, Stephanie M</name>
      </author>
      <author>
        <name>Smith, Lauren</name>
      </author>
      <author>
        <name>Gao, Yu</name>
      </author>
      <author>
        <name>Steinberg, Michael L</name>
      </author>
      <author>
        <name>Cao, Minsong</name>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
    </item>
    <item>
      <title>Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial</title>
      <link>https://escholarship.org/uc/item/3k18x9ps</link>
      <description>Nearly all men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen deprivation therapy (ADT) experience recurrence within 6&amp;nbsp;mo of testosterone recovery. We conducted a single-arm phase 2 trial to evaluate whether addition of dual androgen receptor pathway inhibitors (ARPIs) and metastasis-directed stereotactic body radiotherapy (SBRT) to intermittent ADT improves recurrence rates for men with between one and five nonvisceral, extrapelvic metastases on prostate-specific membrane antigen positron emission tomography/computed tomography after prior radical prostatectomy. Patients received 6&amp;nbsp;mo of androgen annihilation therapy (AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) and metastasis-directed SBRT. The primary endpoint was the percentage of patients with prostate-specific antigen (PSA) &amp;lt;0.05&amp;nbsp;ng/ml 6&amp;nbsp;mo after testosterone recovery (≥150&amp;nbsp;ng/dl), with the study powered to detect an improvement from...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3k18x9ps</guid>
      <pubDate>Wed, 30 Oct 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Nikitas, John</name>
      </author>
      <author>
        <name>Rettig, Matthew</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Shen, John</name>
        <uri>https://orcid.org/0000-0002-6455-5553</uri>
      </author>
      <author>
        <name>Reiter, Robert</name>
      </author>
      <author>
        <name>Lee, Alan</name>
      </author>
      <author>
        <name>Steinberg, Michael L</name>
      </author>
      <author>
        <name>Valle, Luca F</name>
        <uri>https://orcid.org/0000-0002-5781-4174</uri>
      </author>
      <author>
        <name>Sachdeva, Ankush</name>
      </author>
      <author>
        <name>Romero, Tahmineh</name>
      </author>
      <author>
        <name>Calais, Jeremie</name>
        <uri>https://orcid.org/0000-0002-8839-4379</uri>
      </author>
      <author>
        <name>Czernin, Johannes</name>
      </author>
      <author>
        <name>Nickols, Nicholas G</name>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
    </item>
    <item>
      <title>Endovascular transmural access to carotid artery perivascular tissues: safety assessment of a novel technique</title>
      <link>https://escholarship.org/uc/item/39c0s8md</link>
      <description>BACKGROUND: Recent advances in endovascular devices have allowed access and targeting of perivascular tissues of the peripheral circulation. The perivascular tissues of the cervical and cranial circulations have many important structures of clinical significance, yet the feasibility and safety of such an approach has not been demonstrated.
OBJECTIVE: To evaluate the safety of a novel endovascular transmural approach to target the perivascular tissues of the common carotid artery in swine.
METHODS: A micro-infusion device was positioned in the carotid arteries of three Yorkshire pigs (six carotid arteries in total), and each carotid artery was punctured 10 times in the same location to gain access to the perivascular tissues. Digital subtraction angiography was used to evaluate vessel injury or contrast extravasation. MRI and MR angiography were used to evaluate evidence of cerebral ischemia or vessel injury. Post-mortem tissue analysis was performed to assess the level of extravascular...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/39c0s8md</guid>
      <pubDate>Wed, 30 Oct 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Kim, Wi Jin</name>
      </author>
      <author>
        <name>Samarage, Hasitha Milan</name>
      </author>
      <author>
        <name>Zarrin, David</name>
      </author>
      <author>
        <name>Goel, Keshav</name>
      </author>
      <author>
        <name>Wang, Anthony C</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
      <author>
        <name>Johnson, Jeremiah</name>
      </author>
      <author>
        <name>Nael, Kambiz</name>
        <uri>https://orcid.org/0000-0002-4194-9488</uri>
      </author>
      <author>
        <name>Colby, Geoffrey P</name>
        <uri>https://orcid.org/0000-0002-3376-0933</uri>
      </author>
    </item>
    <item>
      <title>Metric learning guided sinogram denoising for cone beam CT enhancement</title>
      <link>https://escholarship.org/uc/item/55p6350z</link>
      <description>BACKGROUND: Cone beam computed tomography (CBCT) is a widely available modality, but its clinical utility has been limited by low detail conspicuity and quantitative accuracy. Convenient post-reconstruction denoising is subject to back projected patterned residual, but joint denoise-reconstruction is typically computationally expensive and complex.
PURPOSE: In this study, we develop and evaluate a novel Metric-learning guided wavelet transform reconstruction (MEGATRON) approach to enhance image domain quality with projection-domain processing.
METHODS: Projection domain based processing has the benefit of being simple, efficient, and compatible with various reconstruction toolkit and vendor platforms. However, they also typically show inferior performance in the final reconstructed image, because the denoising goals in projection and image domains do not necessarily align. Motivated by these observations, this work aims to translate the demand for quality enhancement from the...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/55p6350z</guid>
      <pubDate>Wed, 9 Oct 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Li, Haoran</name>
      </author>
      <author>
        <name>Tsai, Yun‐Han</name>
      </author>
      <author>
        <name>Liu, Hengjie</name>
        <uri>https://orcid.org/0000-0001-5890-2291</uri>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
    </item>
    <item>
      <title>Sub-chronic nicotine exposure influences methamphetamine self-administration and dopamine overflow in a sex-and genotype-dependent manner in humanized CHRNA6 3′-UTR SNP (rs2304297) adolescent rats</title>
      <link>https://escholarship.org/uc/item/3td7q2pf</link>
      <description>&lt;b&gt;Introduction:&lt;/b&gt; The rewarding effects of drugs of abuse are associated with the dopaminergic system in the limbic circuitry. Nicotine exposure during adolescence is linked to increased use of drugs of abuse with nicotine and methamphetamine (METH) commonly used together. Nicotine acts on neuronal nicotinic acetylcholine receptor (nAChR) systems, critical for reward processing and drug reinforcement, while METH leads to a higher dopamine (DA) efflux in brain reward regions. A human single nucleotide polymorphism (SNP) in the 3'-untranslated region (UTR) of the α6 nicotinic receptor subunit gene (&lt;i&gt;CHRNA&lt;/i&gt;6, rs2304297), has been linked with tobacco/nicotine and general substance use during adolescence. Using CRISPR-Cas9 genomic engineering, our lab recapitulated the &lt;i&gt;CHRNA&lt;/i&gt;6 3'UTR&lt;sup&gt;C123G&lt;/sup&gt; SNP, generating α6&lt;sup&gt;CC&lt;/sup&gt; and α6&lt;sup&gt;GG&lt;/sup&gt; allele carriers in Sprague Dawley rats. We hypothesized the &lt;i&gt;CHRNA&lt;/i&gt;6 3'UTR&lt;sup&gt;C123G&lt;/sup&gt; SNP would sex- and genotype-dependently...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3td7q2pf</guid>
      <pubDate>Thu, 19 Sep 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Carreño, Diana</name>
      </author>
      <author>
        <name>Facundo, Antonella</name>
      </author>
      <author>
        <name>Cardenas, Anjelica</name>
      </author>
      <author>
        <name>Lotfipour, Shahrdad</name>
        <uri>https://orcid.org/0000-0003-3437-9410</uri>
      </author>
    </item>
    <item>
      <title>All for one, though not one for all: team players in normal tissue radiobiology</title>
      <link>https://escholarship.org/uc/item/7f4992st</link>
      <description>PURPOSE: As part of the special issue on 'Women in Science', this review offers a perspective on past and ongoing work in the field of normal (non-cancer) tissue radiation biology, highlighting the work of many of the leading contributors to this field of research. We discuss some of the hypotheses that have guided investigations, with a focus on some of the critical organs considered dose-limiting with respect to radiation therapy, and speculate on where the field needs to go in the future.
CONCLUSIONS: The scope of work that makes up normal tissue radiation biology has and continues to play a pivotal role in the radiation sciences, ensuring the most effective application of radiation in imaging and therapy, as well as contributing to radiation protection efforts. However, despite the proven historical value of preclinical findings, recent decades have seen clinical practice move ahead with altered fractionation scheduling based on empirical observations, with little to no (or...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7f4992st</guid>
      <pubDate>Thu, 29 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Boerma, Marjan</name>
      </author>
      <author>
        <name>Davis, Catherine M</name>
      </author>
      <author>
        <name>Jackson, Isabel L</name>
      </author>
      <author>
        <name>Schaue, Dörthe</name>
      </author>
      <author>
        <name>Williams, Jacqueline P</name>
      </author>
    </item>
    <item>
      <title>Adaptation of the Tumor Antigen Presentation Machinery to Ionizing Radiation.</title>
      <link>https://escholarship.org/uc/item/6z08p5rn</link>
      <description>Ionizing radiation (IR) can reprogram proteasome structure and function in cells and tissues. In this article, we show that IR can promote immunoproteasome synthesis with important implications for Ag processing and presentation and tumor immunity. Irradiation of a murine fibrosarcoma (FSA) induced dose-dependent de novo biosynthesis of the immunoproteasome subunits LMP7, LMP2, and Mecl-1, in concert with other changes in the Ag-presentation machinery (APM) essential for CD8+ T cell-mediated immunity, including enhanced expression of MHC class I (MHC-I), β2-microglobulin, transporters associated with Ag processing molecules, and their key transcriptional activator NOD-like receptor family CARD domain containing 5. In contrast, in another less immunogenic, murine fibrosarcoma (NFSA), LMP7 transcripts and expression of components of the immunoproteasome and the APM were muted after IR, which affected MHC-I expression and CD8+ T lymphocyte infiltration into NFSA tumors in&amp;nbsp;vivo....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6z08p5rn</guid>
      <pubDate>Thu, 29 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Lee, Mi-Heon</name>
      </author>
      <author>
        <name>Ratanachan, Duang</name>
      </author>
      <author>
        <name>Wang, Zitian</name>
      </author>
      <author>
        <name>Hack, Jacob</name>
      </author>
      <author>
        <name>Adbulrahman, Lobna</name>
      </author>
      <author>
        <name>Shamlin, Nicholas P</name>
      </author>
      <author>
        <name>Kalayjian, Mirna</name>
      </author>
      <author>
        <name>Nesseler, Jean Philippe</name>
      </author>
      <author>
        <name>Ganapathy, Ekambaram</name>
      </author>
      <author>
        <name>Nguyen, Christine</name>
      </author>
      <author>
        <name>Ratikan, Josephine A</name>
      </author>
      <author>
        <name>Cacalano, Nicolas A</name>
      </author>
      <author>
        <name>Austin, David</name>
      </author>
      <author>
        <name>Damoiseaux, Robert</name>
        <uri>https://orcid.org/0000-0002-7611-7534</uri>
      </author>
      <author>
        <name>DiPardo, Benjamin J</name>
      </author>
      <author>
        <name>Graham, Danielle S</name>
      </author>
      <author>
        <name>Kalbasi, Anusha</name>
      </author>
      <author>
        <name>Sayre, James W</name>
      </author>
      <author>
        <name>McBride, William H</name>
      </author>
      <author>
        <name>Schaue, Dörthe</name>
      </author>
    </item>
    <item>
      <title>T Cells Contribute to Pathological Responses in the Non-Targeted Rat Heart following Irradiation of the Kidneys</title>
      <link>https://escholarship.org/uc/item/0798z4s6</link>
      <description>Heart disease is a significant adverse event caused by radiotherapy for some cancers. Identifying the origins of radiogenic heart disease will allow therapies to be developed. Previous studies showed non-targeted effects manifest as fibrosis in the non-irradiated heart after 120 days following targeted X-irradiation of the kidneys with 10 Gy in WAG/RijCmcr rats. To demonstrate the involvement of T cells in driving pathophysiological responses in the out-of-field heart, and to characterize the timing of immune cell engagement, we created and validated a T cell knock downrat on the WAG genetic backgrou nd. Irradiation of the kidneys with 10 Gy of X-rays in wild-type rats resulted in infiltration of T cells, natural killer cells, and macrophages after 120 days, and none of these after 40 days, suggesting immune cell engagement is a late response. The radiation nephropathy and cardiac fibrosis that resulted in these animals after 120 days was significantly decreased in irradiated...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0798z4s6</guid>
      <pubDate>Thu, 29 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Lenarczyk, Marek</name>
      </author>
      <author>
        <name>Alsheikh, Ammar J</name>
      </author>
      <author>
        <name>Cohen, Eric P</name>
      </author>
      <author>
        <name>Schaue, Dörthe</name>
      </author>
      <author>
        <name>Kronenberg, Amy</name>
      </author>
      <author>
        <name>Geurts, Aron</name>
      </author>
      <author>
        <name>Klawikowski, Slade</name>
      </author>
      <author>
        <name>Mattson, David</name>
      </author>
      <author>
        <name>Baker, John E</name>
      </author>
    </item>
    <item>
      <title>Total marrow irradiation reduces organ damage and enhances tissue repair with the potential to increase the targeted dose of bone marrow in both young and old mice</title>
      <link>https://escholarship.org/uc/item/03c9c1rc</link>
      <description>Total body irradiation (TBI) is a commonly used conditioning regimen for hematopoietic stem cell transplant (HCT), but dose heterogeneity and long-term organ toxicity pose significant challenges. Total marrow irradiation (TMI), an evolving radiation conditioning regimen for HCT can overcome the limitations of TBI by delivering the prescribed dose targeted to the bone marrow (BM) while sparing organs at risk. Recently, our group demonstrated that TMI up to 20 Gy in relapsed/refractory AML patients was feasible and efficacious, significantly improving 2-year overall survival compared to the standard treatment. Whether such dose escalation is feasible in elderly patients, and how the organ toxicity profile changes when switching to TMI in patients of all ages are critical questions that need to be addressed. We used our recently developed 3D image-guided preclinical TMI model and evaluated the radiation damage and its repair in key dose-limiting organs in young (~8 weeks) and old...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/03c9c1rc</guid>
      <pubDate>Thu, 29 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Lim, Ji Eun</name>
      </author>
      <author>
        <name>Madabushi, Srideshikan Sargur</name>
      </author>
      <author>
        <name>Vishwasrao, Paresh</name>
      </author>
      <author>
        <name>Song, Joo Y</name>
      </author>
      <author>
        <name>Abdelhamid, Amr MH</name>
      </author>
      <author>
        <name>Ghimire, Hemendra</name>
      </author>
      <author>
        <name>Vanishree, VL</name>
      </author>
      <author>
        <name>Lamba, Jatinder K</name>
      </author>
      <author>
        <name>Dandapani, Savita</name>
      </author>
      <author>
        <name>Salhotra, Amandeep</name>
      </author>
      <author>
        <name>Lemecha, Mengistu</name>
      </author>
      <author>
        <name>Pierini, Antonio</name>
      </author>
      <author>
        <name>Zhao, Daohong</name>
      </author>
      <author>
        <name>Storme, Guy</name>
      </author>
      <author>
        <name>Holtan, Shernan</name>
      </author>
      <author>
        <name>Aristei, Cynthia</name>
      </author>
      <author>
        <name>Schaue, Dorthe</name>
      </author>
      <author>
        <name>Al Malki, Monzr</name>
      </author>
      <author>
        <name>Hui, Susanta K</name>
      </author>
    </item>
    <item>
      <title>pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells</title>
      <link>https://escholarship.org/uc/item/6b52p91z</link>
      <description>BACKGROUND: Given the invasive nature of glioblastoma, tumor cells exist beyond the contrast-enhancing (CE) region targeted during treatment. However, areas of non-enhancing (NE) tumors are difficult to visualize and delineate from edematous tissue. Amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) is a pH-sensitive molecular magnetic resonance imaging technique that was evaluated in its ability to identify infiltrating NE tumors and prognosticate survival.
METHODS: In this prospective study, CEST-EPI was obtained in 30 patients and areas with elevated CEST contrast ("CEST+" based on the asymmetry in magnetization transfer ratio: MTRasym at 3 ppm) within NE regions were quantitated. Median MTRasym at 3 ppm and volume of CEST + NE regions were correlated with progression-free survival (PFS). In 20 samples from 14 patients, image-guided biopsies of these areas were obtained to correlate MTRasym at 3 ppm to tumor and non-tumor cell burden using immunohistochemistry.
RESULTS:...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6b52p91z</guid>
      <pubDate>Wed, 21 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Patel, Kunal S</name>
      </author>
      <author>
        <name>Yao, Jingwen</name>
      </author>
      <author>
        <name>Cho, Nicholas S</name>
      </author>
      <author>
        <name>Sanvito, Francesco</name>
        <uri>https://orcid.org/0000-0003-3379-9958</uri>
      </author>
      <author>
        <name>Tessema, Kaleab</name>
      </author>
      <author>
        <name>Alvarado, Alvaro</name>
        <uri>https://orcid.org/0000-0002-4049-8400</uri>
      </author>
      <author>
        <name>Dudley, Lindsey</name>
      </author>
      <author>
        <name>Rodriguez, Fausto</name>
      </author>
      <author>
        <name>Everson, Richard</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Cloughesy, Timothy F</name>
      </author>
      <author>
        <name>Salamon, Noriko</name>
        <uri>https://orcid.org/0000-0002-3520-9467</uri>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Kornblum, Harley I</name>
      </author>
      <author>
        <name>Ellingson, Benjamin M</name>
      </author>
    </item>
    <item>
      <title>Automatic detection and segmentation of multiple brain metastases on magnetic resonance image using asymmetric UNet architecture</title>
      <link>https://escholarship.org/uc/item/1nd0p7ps</link>
      <description>Detection of brain metastases is a paramount task in cancer management due both to the number of high-risk patients and the difficulty of achieving consistent detection. In this study, we aim to improve the accuracy of automated brain metastasis (BM) detection methods using a novel asymmetric UNet (asym-UNet) architecture. An end-to-end asymmetric 3D-UNet architecture, with two down-sampling arms and one up-sampling arm, was constructed to capture the imaging features. The two down-sampling arms were trained using two different kernels (3 × 3 × 3 and 1 × 1 × 3, respectively) with the kernel (1 × 1 × 3) dominating the learning. As a comparison, vanilla single 3D UNets were trained with different kernels and evaluated using the same datasets. Voxel-based Dice similarity coefficient (DSC&lt;sub&gt;v&lt;/sub&gt;), sensitivity (S &lt;sub&gt;v&lt;/sub&gt;), precision (P &lt;sub&gt;v&lt;/sub&gt;), BM-based sensitivity (S &lt;sub&gt;BM&lt;/sub&gt;), and false detection rate (F &lt;sub&gt;BM&lt;/sub&gt;) were used to evaluate model performance....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1nd0p7ps</guid>
      <pubDate>Wed, 21 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Cao, Yufeng</name>
      </author>
      <author>
        <name>Vassantachart, April</name>
      </author>
      <author>
        <name>Ye, Jason C</name>
      </author>
      <author>
        <name>Yu, Cheng</name>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
      <author>
        <name>Sheng, Ke</name>
      </author>
      <author>
        <name>Lao, Yi</name>
      </author>
      <author>
        <name>Shen, Zhilei Liu</name>
      </author>
      <author>
        <name>Balik, Salim</name>
      </author>
      <author>
        <name>Bian, Shelly</name>
      </author>
      <author>
        <name>Zada, Gabriel</name>
      </author>
      <author>
        <name>Shiu, Almon</name>
      </author>
      <author>
        <name>Chang, Eric L</name>
      </author>
      <author>
        <name>Yang, Wensha</name>
        <uri>https://orcid.org/0000-0002-7274-9454</uri>
      </author>
    </item>
    <item>
      <title>Tumor Size Matters—Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy</title>
      <link>https://escholarship.org/uc/item/7b31m16z</link>
      <description>The purpose of this study was to determine the dynamic contributions of different immune cell subsets to primary and abscopal tumor regression after hypofractionated radiation therapy (hRT) and the impact of anti-PD-1 therapy. A bilateral syngeneic FSA1 fibrosarcoma model was used in immunocompetent C3H mice, with delayed inoculation to mimic primary and microscopic disease. The effect of tumor burden on intratumoral and splenic immune cell content was delineated as a prelude to hRT on macroscopic T1 tumors with 3 fractions of 8 Gy while microscopic T2 tumors were left untreated. This was performed with and without systemic anti-PD-1. Immune profiles within T1 and T2 tumors and in spleen changed drastically with tumor burden in untreated mice with infiltrating CD4+ content declining, while the proportion of CD4+ Tregs rose. Myeloid cell representation escalated in larger tumors, resulting in major decreases in the lymphoid:myeloid ratios. In general, activation of Tregs and myeloid-derived...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7b31m16z</guid>
      <pubDate>Sun, 18 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Nesseler, Jean Philippe</name>
      </author>
      <author>
        <name>Lee, Mi-Heon</name>
      </author>
      <author>
        <name>Nguyen, Christine</name>
      </author>
      <author>
        <name>Kalbasi, Anusha</name>
        <uri>https://orcid.org/0000-0001-8692-1457</uri>
      </author>
      <author>
        <name>Sayre, James W</name>
      </author>
      <author>
        <name>Romero, Tahmineh</name>
      </author>
      <author>
        <name>Nickers, Philippe</name>
      </author>
      <author>
        <name>McBride, William H</name>
      </author>
      <author>
        <name>Schaue, Dörthe</name>
      </author>
    </item>
    <item>
      <title>Acute Effects and the Dreamy State Evoked by Deep Brain Electrical Stimulation of the Amygdala: Associations of the Amygdala in Human Dreaming, Consciousness, Emotions, and Creativity</title>
      <link>https://escholarship.org/uc/item/41d0g9jj</link>
      <description>Accurate localization of complex human experiences such as emotions, dreaming, creativity, and consciousness to specific cerebral structures or neural networks has remained elusive despite technological advances. We report the use of acute deep brain stimulation (DBS) to evoke behavioral and emotional effects by applying electrical stimulation (ES) at various voltage strengths to the basolateral and central subnuclei of the amygdala in addition to the head of hippocampus (HC) for two subjects with medically refractory post-traumatic stress disorder (PTSD). Our results suggest that the amygdala could be a node in a neural network responsible for the generation of complex vivid mental imagery and integrated sensory experiences similar to John Hughlings Jackson's "dreamy state" and "double consciousness," which have been classically associated with temporal lobe epilepsy during uncinate seizures. That we were able to elicit similar vivid, dynamic, complex, bizarre, and original mental...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/41d0g9jj</guid>
      <pubDate>Sun, 18 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Lai, George</name>
      </author>
      <author>
        <name>Langevin, Jean-Philippe</name>
      </author>
      <author>
        <name>Koek, Ralph J</name>
      </author>
      <author>
        <name>Krahl, Scott E</name>
      </author>
      <author>
        <name>Bari, Ausaf A</name>
        <uri>https://orcid.org/0000-0002-5279-5023</uri>
      </author>
      <author>
        <name>Chen, James WY</name>
      </author>
    </item>
    <item>
      <title>Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity</title>
      <link>https://escholarship.org/uc/item/80g329w2</link>
      <description>Type I interferon (IFN-I) and IFN-γ foster antitumor immunity by facilitating T&amp;nbsp;cell responses. Paradoxically, IFNs may promote T&amp;nbsp;cell exhaustion by activating immune checkpoints. The downstream regulators of these disparate responses are incompletely understood. Here, we describe how interferon regulatory factor 1 (IRF1) orchestrates these opposing effects of IFNs. IRF1 expression in tumor cells blocks Toll-like receptor- and IFN-I-dependent host antitumor immunity by preventing interferon-stimulated gene (ISG) and effector programs in immune cells. In contrast, expression of IRF1 in the host is required for antitumor immunity. Mechanistically, IRF1 binds distinctly or together with STAT1 at promoters of immunosuppressive but not immunostimulatory ISGs in tumor cells. Overexpression of programmed cell death ligand 1 (PD-L1) in Irf1&lt;sup&gt;-/-&lt;/sup&gt; tumors only partially restores tumor growth, suggesting multifactorial effects of IRF1 on antitumor immunity. Thus, we identify...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/80g329w2</guid>
      <pubDate>Sat, 17 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Purbey, Prabhat K</name>
        <uri>https://orcid.org/0000-0001-6373-6283</uri>
      </author>
      <author>
        <name>Seo, Joowon</name>
      </author>
      <author>
        <name>Paul, Manash K</name>
      </author>
      <author>
        <name>Iwamoto, Keisuke S</name>
      </author>
      <author>
        <name>Daly, Allison E</name>
      </author>
      <author>
        <name>Feng, An-Chieh</name>
      </author>
      <author>
        <name>Champhekar, Ameya S</name>
      </author>
      <author>
        <name>Langerman, Justin</name>
      </author>
      <author>
        <name>Campbell, Katie M</name>
      </author>
      <author>
        <name>Schaue, Dörthe</name>
      </author>
      <author>
        <name>McBride, William H</name>
      </author>
      <author>
        <name>Dubinett, Steven M</name>
      </author>
      <author>
        <name>Ribas, Antoni</name>
        <uri>https://orcid.org/0000-0003-3669-8458</uri>
      </author>
      <author>
        <name>Smale, Stephen T</name>
      </author>
      <author>
        <name>Scumpia, Philip O</name>
      </author>
    </item>
    <item>
      <title>Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma</title>
      <link>https://escholarship.org/uc/item/0cj235rr</link>
      <description>Glioblastoma (GBM) is the most common malignant primary brain tumor and remains incurable. Previous work has shown that systemic administration of Decitabine (DAC) induces sufficient expression of cancer-testis antigens (CTA) in GBM for targeting by adoptive T-cell therapy in vivo. However, the mechanisms by which DAC enhances immunogenicity in GBM remain to be elucidated. Using New York esophageal squamous cell carcinoma 1 (NY-ESO-1) as a representative inducible CTA, we demonstrate in patient tissue, immortalized glioma cells, and primary patient-derived gliomaspheres that basal CTA expression is restricted by promoter hypermethylation in gliomas. DAC treatment of glioma cells specifically inhibits DNA methylation silencing to render NY-ESO-1 and other CTA into inducible tumor antigens at single-cell resolution. Functionally, NY-ESO-1 T-cell receptor-engineered effector cell targeting of DAC-induced antigen in primary glioma cells promotes specific and polyfunctional T-cell...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0cj235rr</guid>
      <pubDate>Mon, 12 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Lai, Thomas J</name>
      </author>
      <author>
        <name>Sun, Lu</name>
      </author>
      <author>
        <name>Li, Kevin</name>
      </author>
      <author>
        <name>Prins, Terry J</name>
      </author>
      <author>
        <name>Treger, Janet</name>
      </author>
      <author>
        <name>Li, Tie</name>
      </author>
      <author>
        <name>Sun, Matthew Z</name>
      </author>
      <author>
        <name>Nathanson, David A</name>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Lai, Albert</name>
      </author>
      <author>
        <name>Prins, Robert M</name>
        <uri>https://orcid.org/0000-0002-6282-6583</uri>
      </author>
      <author>
        <name>Everson, Richard G</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
    </item>
    <item>
      <title>Pathophysiology and Management of Chest Wall Pain after Surgical and Non-Surgical Local Therapies for Lung Cancer</title>
      <link>https://escholarship.org/uc/item/6v080738</link>
      <description>Chest wall pain syndromes can emerge following local therapies for lung cancer and can adversely affect patients' quality-of-life. This can occur after lung surgery, radiation therapy, or percutaneous image-guided thermal ablation. This review describes the multifactorial pathophysiology of chest wall pain syndromes that develop following surgical and non-surgical local therapies for lung cancer and summarizes evidence-based management strategies for inflammatory, neuropathic, myofascial, and osseous pain. It discusses a step-wise approach to treating chest wall pain that begins with non-opioid oral analgesics and includes additional pharmacologic treatments as clinically indicated, such as anticonvulsants, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, and various topical treatments. For myofascial pain, physical medicine techniques, such as acupuncture, trigger point injections, deep tissue massage, and intercostal myofascial release can also offer...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6v080738</guid>
      <pubDate>Sat, 10 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Nikitas, John</name>
      </author>
      <author>
        <name>Yanagawa, Jane</name>
      </author>
      <author>
        <name>Sacks, Sandra</name>
      </author>
      <author>
        <name>Hui, Edward K</name>
      </author>
      <author>
        <name>Lee, Alan</name>
      </author>
      <author>
        <name>Deng, Jie</name>
      </author>
      <author>
        <name>Abtin, Fereidoun</name>
        <uri>https://orcid.org/0000-0003-2927-0883</uri>
      </author>
      <author>
        <name>Suh, Robert</name>
      </author>
      <author>
        <name>Lee, Jay M</name>
      </author>
      <author>
        <name>Toste, Paul</name>
      </author>
      <author>
        <name>Burt, Bryan M</name>
      </author>
      <author>
        <name>Revels, Sha’Shonda L</name>
      </author>
      <author>
        <name>Cameron, Robert B</name>
      </author>
      <author>
        <name>Moghanaki, Drew</name>
        <uri>https://orcid.org/0000-0002-5129-2184</uri>
      </author>
    </item>
    <item>
      <title>Multimodality Therapies for Localized Prostate Cancer</title>
      <link>https://escholarship.org/uc/item/32v1c0c7</link>
      <description>Purpose of ReviewMultimodality therapy including radical prostatectomy, radiation therapy, and hormone therapy are frequently deployed in the management of localized prostate cancer. We sought to perform a critical appraisal of the most contemporary literature focusing on the multimodality management of localized prostate cancer.Recent FindingsMen who are ideal candidates for multimodality therapy include those with unfavorable intermediate-risk disease, high-risk disease, and very high-risk disease. Enhancements in both systemic agents (including second-generation antiandrogens) as well as localized therapies (such as stereotactic body radiotherapy and brachytherapy) are refining the optimal balance between the use of systemic and local therapies for localized prostate cancer. Genomic predictors are emerging as critical tools for more precisely allocating treatment intensification with multimodality therapies as well as treatment de-intensification.SummaryClose collaboration...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/32v1c0c7</guid>
      <pubDate>Thu, 8 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Valle, Luca F</name>
        <uri>https://orcid.org/0000-0002-5781-4174</uri>
      </author>
      <author>
        <name>Jiang, Tommy</name>
      </author>
      <author>
        <name>Weiner, Adam B</name>
      </author>
      <author>
        <name>Reiter, Robert E</name>
      </author>
      <author>
        <name>Rettig, Matthew B</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Shen, John</name>
        <uri>https://orcid.org/0000-0002-6455-5553</uri>
      </author>
      <author>
        <name>Chang, Albert J</name>
      </author>
      <author>
        <name>Nickols, Nicholas G</name>
      </author>
      <author>
        <name>Steinberg, Michael L</name>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
    </item>
    <item>
      <title>Prostate bed and organ-at-risk deformation: Prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy</title>
      <link>https://escholarship.org/uc/item/8dw3v4sg</link>
      <description>PURPOSE: Stereotactic body radiotherapy (SBRT) in the post-prostatectomy setting is investigational. A major concern is the deformable prostate bed clinical target volume (CTV) and the closely juxtaposed organs-at-risk (OARs). We report a volumetric and dosimetric analysis of kilovoltage cone-beam CT (CBCT) data from the first 18 patients enrolled on a phase II trial of post-prostatectomy SBRT. With instructions on bladder filling and rectal preparation, we hypothesized acceptable CTV coverage while minimal overdosing to OARs could be achieved.
METHODS: All patients received 5 fractions of 6-6.8&amp;nbsp;Gy to the prostate bed. CBCT were taken prior to and halfway through each fraction. CTV and OARs were contoured for each CBCT. Changes in inter- and intra-fraction volume and dose were calculated. Relative changes in CTV V95%, bladder V32.5&amp;nbsp;Gy, and rectal V32.5&amp;nbsp;Gy and V27.5&amp;nbsp;Gy were evaluated.
RESULTS: Interfraction CTV volume remained stable, with median change +5.69%...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8dw3v4sg</guid>
      <pubDate>Sat, 3 Aug 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Yoon, Stephanie</name>
      </author>
      <author>
        <name>Cao, Minsong</name>
      </author>
      <author>
        <name>Aghdam, Nima</name>
      </author>
      <author>
        <name>Shabsovich, David</name>
      </author>
      <author>
        <name>Kahlon, Sartajdeep</name>
      </author>
      <author>
        <name>Ballas, Leslie</name>
      </author>
      <author>
        <name>Collins, Sean</name>
      </author>
      <author>
        <name>Steinberg, Michael Lee</name>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
    </item>
    <item>
      <title>Novel endovascular transmural technique for pharmacological block of superior cervical ganglion prevents sympathetic-mediated cerebral vasospasm</title>
      <link>https://escholarship.org/uc/item/9fg9t187</link>
      <description>BACKGROUND: Sympathetic-mediated vasoconstriction from the superior cervical ganglion (SCG) is a significant contributor to cerebral vasospasm. Inhibition of the SCG has been shown to improve cerebral blood flow and reverse cerebral vasospasm in swine models. We evaluated the efficacy of a novel minimally invasive endovascular approach to target and pharmacologically inhibit the SCG, using a Micro-Infusion Device for transmural drug delivery.
METHODS: Eight SCGs in four Yorkshire swine were surgically identified. After confirming appropriate sympathetic-mediated intracranial vasoconstriction response with SCG stimulation, an endovascular Micro-Infusion Device was used for transmural targeting of the SCG and delivery of 1.5-2 mL of 1% lidocaine-contrast mixture to the perivascular space. Digital subtraction angiography was obtained at: (1) baseline; (2) with SCG stimulation; and (3) after lidocaine delivery to the SCG using the Micro-Infusion Device with concurrent SCG stimulation....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9fg9t187</guid>
      <pubDate>Wed, 24 Jul 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Kim, Wi Jin</name>
      </author>
      <author>
        <name>Samarage, Hasitha Milan</name>
      </author>
      <author>
        <name>Jafari, Matiar</name>
      </author>
      <author>
        <name>Zarrin, David</name>
      </author>
      <author>
        <name>Goel, Keshav</name>
      </author>
      <author>
        <name>Qi, Xin</name>
      </author>
      <author>
        <name>Wang, Anthony C</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
      <author>
        <name>Johnson, Jeremiah</name>
      </author>
      <author>
        <name>Colby, Geoffrey P</name>
        <uri>https://orcid.org/0000-0002-3376-0933</uri>
      </author>
    </item>
    <item>
      <title>Radiation‐induced tissue damage and response</title>
      <link>https://escholarship.org/uc/item/81w6z83z</link>
      <description>Normal tissue responses to ionizing radiation have been a major subject for study since the discovery of X-rays at the end of the 19th century. Shortly thereafter, time-dose relationships were established for some normal tissue endpoints that led to investigations into how the size of dose per fraction and the quality of radiation affected outcome. The assessment of the radiosensitivity of bone marrow stem cells using colony-forming assays by Till and McCulloch prompted the establishment of in situ clonogenic assays for other tissues that added to the radiobiology toolbox. These clonogenic and functional endpoints enabled mathematical modeling to be performed that elucidated how tissue structure, and in particular turnover time, impacted clinically relevant fractionated radiation schedules. More recently, lineage tracing technology, advanced imaging and single cell sequencing have shed further light on the behavior of cells within stem, and other, cellular compartments, both in...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/81w6z83z</guid>
      <pubDate>Sun, 21 Jul 2024 00:00:00 +0000</pubDate>
      <author>
        <name>McBride, William H</name>
      </author>
      <author>
        <name>Schaue, Dörthe</name>
      </author>
    </item>
    <item>
      <title>MR-LINAC, a New Partner in Radiation Oncology: Current Landscape</title>
      <link>https://escholarship.org/uc/item/7kg6k4hz</link>
      <description>Technological advances in radiation oncology are oriented towards improving treatment precision and tumor control. Among these advances, magnetic-resonance-image-guided radiation therapy (MRgRT) stands out, with technological advances to deliver targeted treatments adapted to a tumor's anatomy on the day while minimizing incidental exposure to organs at risk, offering an unprecedented therapeutic advantage compared to X-ray-based IGRT delivery systems. This new technology changes the traditional workflow in radiation oncology and requires an evolution in team coordination to administer more precise treatments. Once implemented, it paves the way for newer indication for radiation therapy to safely deliver higher doses than ever before, with better preservation of healthy tissues to optimize patient outcomes. In this narrative review, we assess the technical aspects of the novel linear accelerators that can deliver MRgRT and summarize the available published experience to date,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7kg6k4hz</guid>
      <pubDate>Thu, 18 Jul 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Ocanto, Abrahams</name>
      </author>
      <author>
        <name>Torres, Lisselott</name>
      </author>
      <author>
        <name>Montijano, Miguel</name>
      </author>
      <author>
        <name>Rincón, Diego</name>
      </author>
      <author>
        <name>Fernández, Castalia</name>
      </author>
      <author>
        <name>Sevilla, Beatriz</name>
      </author>
      <author>
        <name>Gonsalves, Daniela</name>
      </author>
      <author>
        <name>Teja, Macarena</name>
      </author>
      <author>
        <name>Guijarro, Marcos</name>
      </author>
      <author>
        <name>Glaría, Luis</name>
      </author>
      <author>
        <name>Hernánz, Raúl</name>
      </author>
      <author>
        <name>Zafra-Martin, Juan</name>
      </author>
      <author>
        <name>Sanmamed, Noelia</name>
      </author>
      <author>
        <name>Kishan, Amar</name>
      </author>
      <author>
        <name>Alongi, Filippo</name>
      </author>
      <author>
        <name>Moghanaki, Drew</name>
        <uri>https://orcid.org/0000-0002-5129-2184</uri>
      </author>
      <author>
        <name>Nagar, Himanshu</name>
      </author>
      <author>
        <name>Couñago, Felipe</name>
      </author>
    </item>
    <item>
      <title>Association of Rurality With Annual Repeat Lung Cancer Screening in the Veterans Health Administration</title>
      <link>https://escholarship.org/uc/item/5pf651cg</link>
      <description>PURPOSE: Lung cancer causes the largest number of cancer-related deaths in the United States. Lung cancer incidence rates, mortality rates, and rates of advanced stage disease are higher among those who live in rural areas. Known disparities in lung cancer outcomes between rural and nonrural populations may be in part because of barriers faced by rural populations. The authors tested the hypothesis that among Veterans who receive initial lung cancer screening, rural Veterans would be less likely to complete annual repeat screening than nonrural Veterans.
METHODS: A retrospective cohort study was conducted of 10 Veterans Affairs medical centers from 2015 to 2019. Rural and nonrural Veterans undergoing lung cancer screening were identified. Rural status was defined using the rural-urban commuting area codes. The primary outcome was annual repeat lung cancer screening in the 9- to 15-month window (primary analysis) and 31-day to 18-month window (sensitivity analysis) after the first...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5pf651cg</guid>
      <pubDate>Thu, 18 Jul 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Spalluto, Lucy B</name>
      </author>
      <author>
        <name>Lewis, Jennifer A</name>
      </author>
      <author>
        <name>Samuels, Lauren R</name>
      </author>
      <author>
        <name>Callaway-Lane, Carol</name>
      </author>
      <author>
        <name>Matheny, Michael E</name>
      </author>
      <author>
        <name>Denton, Jason</name>
      </author>
      <author>
        <name>Robles, Jennifer A</name>
      </author>
      <author>
        <name>Dittus, Robert S</name>
      </author>
      <author>
        <name>Yankelevitz, David F</name>
      </author>
      <author>
        <name>Henschke, Claudia I</name>
      </author>
      <author>
        <name>Massion, Pierre P</name>
      </author>
      <author>
        <name>Moghanaki, Drew</name>
        <uri>https://orcid.org/0000-0002-5129-2184</uri>
      </author>
      <author>
        <name>Roumie, Christianne L</name>
      </author>
    </item>
    <item>
      <title>Rural barriers and facilitators of lung cancer screening program implementation in the veterans health administration: a qualitative study</title>
      <link>https://escholarship.org/uc/item/1jd1r2g1</link>
      <description>Introduction: To assess healthcare professionals' perceptions of rural barriers and facilitators of lung cancer screening program implementation in a Veterans Health Administration (VHA) setting through a series of one-on-one interviews with healthcare team members.
Methods: Based on measures developed using Reach Effectiveness Adoption Implementation Maintenance (RE-AIM), we conducted a cross-sectional qualitative study consisting of one-on-one semi-structured telephone interviews with VHA healthcare team members at 10 Veterans Affairs medical centers (VAMCs) between December 2020 and September 2021. An iterative inductive and deductive approach was used for qualitative analysis of interview data, resulting in the development of a conceptual model to depict rural barriers and facilitators of lung cancer screening program implementation.
Results: A total of 30 interviews were completed among staff, providers, and lung cancer screening program directors and a conceptual model of...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1jd1r2g1</guid>
      <pubDate>Thu, 18 Jul 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Lewis, Jennifer A</name>
      </author>
      <author>
        <name>Bonnet, Kemberlee</name>
      </author>
      <author>
        <name>Schlundt, David G</name>
      </author>
      <author>
        <name>Byerly, Susan</name>
      </author>
      <author>
        <name>Lindsell, Christopher J</name>
      </author>
      <author>
        <name>Henschke, Claudia I</name>
      </author>
      <author>
        <name>Yankelevitz, David F</name>
      </author>
      <author>
        <name>York, Sally J</name>
      </author>
      <author>
        <name>Hendler, Fred</name>
      </author>
      <author>
        <name>Dittus, Robert S</name>
      </author>
      <author>
        <name>Vogus, Timothy J</name>
      </author>
      <author>
        <name>Kripalani, Sunil</name>
      </author>
      <author>
        <name>Moghanaki, Drew</name>
        <uri>https://orcid.org/0000-0002-5129-2184</uri>
      </author>
      <author>
        <name>Audet, Carolyn M</name>
      </author>
      <author>
        <name>Roumie, Christianne L</name>
      </author>
      <author>
        <name>Spalluto, Lucy B</name>
      </author>
    </item>
    <item>
      <title>Activation of the Mevalonate Pathway in Response to Anti-cancer Treatments Drives Glioblastoma Recurrences Through Activation of Rac-1</title>
      <link>https://escholarship.org/uc/item/0j5645tk</link>
      <description>Glioblastoma (GBM) is the deadliest adult brain cancer. Under the current standard of care, almost all patients succumb to the disease and novel treatments are urgently needed. Recognizing that GBMs are addicted to cholesterol, past clinical trials have repurposed statins against GBM but failed. The purpose of this study was to test whether treatments that upregulate the cholesterol biosynthesis pathway in GBM would generate a metabolic vulnerability that can be exploited using statins and to determine the underlying mechanisms.Effects of radiotherapy and temozolomide or dopamine receptor antagonists on the mevalonate pathway in GBM were assessed in vitro and in vivo. The impact of statins on self-renewal of glioma stem cells and median survival was studied. Branches of the mevalonate pathway were probed to identify relevant effector proteins.Cells surviving combination treatments that converge in activating the immediate early response, universally upregulated the mevalonate...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0j5645tk</guid>
      <pubDate>Sat, 6 Jul 2024 00:00:00 +0000</pubDate>
      <author>
        <name>He, Ling</name>
        <uri>https://orcid.org/0000-0002-8692-7530</uri>
      </author>
      <author>
        <name>Ioannidis, Angeliki</name>
      </author>
      <author>
        <name>Hoffman, Carter J</name>
      </author>
      <author>
        <name>Arambula, Evelyn</name>
      </author>
      <author>
        <name>Joshi, Purva</name>
      </author>
      <author>
        <name>Whitelegge, Julian</name>
        <uri>https://orcid.org/0000-0003-2763-7733</uri>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Kornblum, Harley I</name>
      </author>
      <author>
        <name>Pajonk, Frank</name>
      </author>
    </item>
    <item>
      <title>Understanding the Role of Endothelial Cells in Glioblastoma: Mechanisms and Novel Treatments</title>
      <link>https://escholarship.org/uc/item/35x373p7</link>
      <description>Glioblastoma is a highly aggressive neoplasm and the most common primary malignant brain tumor. Endothelial tissue plays a critical role in glioblastoma growth and progression, facilitating angiogenesis, cellular communication, and tumorigenesis. In this review, we present an up-to-date and comprehensive summary of the role of endothelial cells in glioblastomas, along with an overview of recent developments in glioblastoma therapies and tumor endothelial marker identification.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/35x373p7</guid>
      <pubDate>Wed, 26 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Hovis, Gabrielle</name>
      </author>
      <author>
        <name>Chandra, Neha</name>
      </author>
      <author>
        <name>Kejriwal, Nidhi</name>
      </author>
      <author>
        <name>Hsieh, Kaleb Jia-Yi</name>
      </author>
      <author>
        <name>Chu, Alison</name>
      </author>
      <author>
        <name>Yang, Isaac</name>
        <uri>https://orcid.org/0000-0002-5176-5615</uri>
      </author>
      <author>
        <name>Wadehra, Madhuri</name>
      </author>
    </item>
    <item>
      <title>Safety and Efficacy of Laser Interstitial Thermal Therapy as Upfront Therapy in Primary Glioblastoma and IDH-Mutant Astrocytoma: A Meta-Analysis</title>
      <link>https://escholarship.org/uc/item/6sh4878t</link>
      <description>Although primary studies have reported the safety and efficacy of LITT as a primary treatment in glioma, they are limited by sample sizes and institutional variation in stereotactic parameters such as temperature and laser power. The current literature has yet to provide pooled statistics on outcomes solely for primary brain tumors according to the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5). In the present study, we identify recent articles on primary CNS neoplasms treated with LITT without prior intervention, focusing on relationships with molecular profile, PFS, and OS. This meta-analysis includes the extraction of data from primary sources across four databases using the Covidence systematic review manager. The pooled data suggest LITT may be a safe primary management option with tumor ablation rates of 94.8% and 84.6% in IDH-wildtype glioblastoma multiforme (GBM) and IDH-mutant astrocytoma, respectively. For IDH-wildtype GBM, the pooled PFS...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6sh4878t</guid>
      <pubDate>Mon, 24 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Pandey, Aryan</name>
      </author>
      <author>
        <name>Chandla, Anubhav</name>
      </author>
      <author>
        <name>Mekonnen, Mahlet</name>
      </author>
      <author>
        <name>Hovis, Gabrielle EA</name>
      </author>
      <author>
        <name>Teton, Zoe E</name>
      </author>
      <author>
        <name>Patel, Kunal S</name>
      </author>
      <author>
        <name>Everson, Richard G</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Wadehra, Madhuri</name>
      </author>
      <author>
        <name>Yang, Isaac</name>
        <uri>https://orcid.org/0000-0002-5176-5615</uri>
      </author>
    </item>
    <item>
      <title>Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients</title>
      <link>https://escholarship.org/uc/item/6jc4f3j2</link>
      <description>BackgroundImmunotherapeutic approaches, such as dendritic cell (DC) vaccination, have emerged as promising strategies in the treatment of glioblastoma. Despite their promise, however, the absence of objective biomarkers and/or immunological monitoring techniques to assess the clinical efficacy of immunotherapy still remains a primary limitation. To address this, we sought to identify a functional biomarker for anti-tumor immune responsiveness associated with extended survival in glioblastoma patients undergoing DC vaccination.Methods28 patients were enrolled and treated in two different Phase 1&amp;nbsp;DC vaccination clinical trials at UCLA. To assess the anti-tumor immune response elicited by therapy, we studied the functional responsiveness of pre- and post-vaccination peripheral blood lymphocytes (PBLs) to the immunostimulatory cytokines interferon-gamma (IFN-γ) and interleukin-2 (IL-2) in 21 of these patients for whom we had adequate material. Immune responsiveness was quantified...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6jc4f3j2</guid>
      <pubDate>Mon, 17 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Everson, Richard G</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Jin, Richard M</name>
      </author>
      <author>
        <name>Wang, Xiaoyan</name>
      </author>
      <author>
        <name>Safaee, Michael</name>
      </author>
      <author>
        <name>Scharnweber, Rudi</name>
      </author>
      <author>
        <name>Lisiero, Dominique N</name>
      </author>
      <author>
        <name>Soto, Horacio</name>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Prins, Robert M</name>
        <uri>https://orcid.org/0000-0002-6282-6583</uri>
      </author>
    </item>
    <item>
      <title>Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance</title>
      <link>https://escholarship.org/uc/item/4wc6650r</link>
      <description>Subtype-targeted therapies can have a dramatic impact on improving the quality and quantity of life for women suffering from breast cancer. Despite an initial therapeutic response, cancer recurrence and acquired drug-resistance are commonplace. Non-invasive imaging probes that identify drug-resistant lesions are urgently needed to aid in the development of novel drugs and the effective utilization of established therapies for breast cancer. The protease receptor urokinase plasminogen activator receptor (uPAR) is a target that can be exploited for non-invasive imaging. The expression of uPAR has been associated with phenotypically aggressive breast cancer and acquired drug-resistance. Acquired drug-resistance was modeled in cell lines from two different breast cancer subtypes, the uPAR negative luminal A subtype and the uPAR positive triple negative subtype cell line MDA-MB-231. MCF-7 cells, cultured to be resistant to tamoxifen (MCF-7 TamR), were found to significantly over-express...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4wc6650r</guid>
      <pubDate>Mon, 17 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>LeBeau, Aaron M</name>
      </author>
      <author>
        <name>Sevillano, Natalia</name>
      </author>
      <author>
        <name>King, Mandy L</name>
      </author>
      <author>
        <name>Duriseti, Sai</name>
        <uri>https://orcid.org/0000-0002-8073-5132</uri>
      </author>
      <author>
        <name>Murphy, Stephanie T</name>
      </author>
      <author>
        <name>Craik, Charles S</name>
      </author>
      <author>
        <name>Murphy, Laura L</name>
      </author>
      <author>
        <name>VanBrocklin, Henry F</name>
      </author>
    </item>
    <item>
      <title>Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer</title>
      <link>https://escholarship.org/uc/item/3f1442j6</link>
      <description>Patients with primary tumor progression after stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) have a second chance at complete tumor eradication with salvage local therapies, including lung resection, repeat course of SBRT, and percutaneous ablative therapies. In this paper, we presented our institution's initial experience with percutaneous high-dose-rate (HDR) brachyablation for a relapsed stage I NSCLC that had been treated with SBRT 4.3 years earlier. Lung tumor measuring approximately 5 cm in maximum tumor dimension at the time of relapse was histopathologically confirmed to be persistent squamous cell carcinoma, and successfully treated with a single fraction of 24 Gy with HDR brachyablation. Treatment was delivered via two percutaneous catheters inserted under CT-guidance, and treated in less than 20 minutes. The patient was discharged home later the same day without the need for a chest tube, and has been monitored with serial...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3f1442j6</guid>
      <pubDate>Mon, 17 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Wu, Trudy C</name>
      </author>
      <author>
        <name>Lee, Alan</name>
      </author>
      <author>
        <name>Suh, Robert</name>
      </author>
      <author>
        <name>Oughourlian, Talia C</name>
        <uri>https://orcid.org/0000-0001-8133-2928</uri>
      </author>
      <author>
        <name>Abtin, Fereidoun</name>
        <uri>https://orcid.org/0000-0003-2927-0883</uri>
      </author>
      <author>
        <name>Hagio, Mary Ann</name>
      </author>
      <author>
        <name>Park, Sang-June</name>
      </author>
      <author>
        <name>Chang, Albert J</name>
      </author>
      <author>
        <name>Moghanaki, Drew</name>
        <uri>https://orcid.org/0000-0002-5129-2184</uri>
      </author>
    </item>
    <item>
      <title>Delivering High-Quality and Affordable Care Throughout the Cancer Care Continuum</title>
      <link>https://escholarship.org/uc/item/0x8456wv</link>
      <description>The national cost of cancer care is projected to reach $173 billion by 2020, increasing from $125 billion in 2010. This steep upward cost trajectory has placed enormous an financial burden on patients, their families, and society as a whole and raised major concern about the ability of the health care system to provide and sustain high-quality cancer care. To better understand the cost drivers of cancer care and explore approaches that will mitigate the problem, the National Cancer Policy Forum of the Institute of Medicine held a workshop entitled "Delivering Affordable Cancer Care in the 21st Century" in October 2012. Workshop participants included bioethicists, health economists, primary care physicians, and medical, surgical, and radiation oncologists, from both academic and community settings. All speakers expressed a sense of urgency about the affordability of cancer care resulting from the future demographic trend as well as the high cost of emerging cancer therapies and...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0x8456wv</guid>
      <pubDate>Mon, 17 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Shih, Ya-Chen Tina</name>
        <uri>https://orcid.org/0000-0002-9454-4337</uri>
      </author>
      <author>
        <name>Ganz, Patricia A</name>
        <uri>https://orcid.org/0000-0002-1841-4143</uri>
      </author>
      <author>
        <name>Aberle, Denise</name>
        <uri>https://orcid.org/0000-0002-8858-3401</uri>
      </author>
      <author>
        <name>Abernethy, Amy</name>
      </author>
      <author>
        <name>Bekelman, Justin</name>
      </author>
      <author>
        <name>Brawley, Otis</name>
      </author>
      <author>
        <name>Goodwin, James S</name>
      </author>
      <author>
        <name>Hu, Jim C</name>
      </author>
      <author>
        <name>Schrag, Deborah</name>
      </author>
      <author>
        <name>Temel, Jennifer S</name>
      </author>
      <author>
        <name>Schnipper, Lowell</name>
      </author>
    </item>
    <item>
      <title>Development and validation of a measurement‐based source model for kilovoltage cone‐beam CT Monte Carlo dosimetry simulations</title>
      <link>https://escholarship.org/uc/item/8bk0f283</link>
      <description>PURPOSE: The purpose of this study is to adapt an equivalent source model originally developed for conventional CT Monte Carlo dose quantification to the radiation oncology context and validate its application for evaluating concomitant dose incurred by a kilovoltage (kV) cone-beam CT (CBCT) system integrated into a linear accelerator.
METHODS: In order to properly characterize beams from the integrated kV CBCT system, the authors have adapted a previously developed equivalent source model consisting of an equivalent spectrum module that takes into account intrinsic filtration and an equivalent filter module characterizing the added bowtie filtration. An equivalent spectrum was generated for an 80, 100, and 125 kVp beam with beam energy characterized by half-value layer measurements. An equivalent filter description was generated from bowtie profile measurements for both the full- and half-bowtie. Equivalent source models for each combination of equivalent spectrum and filter...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8bk0f283</guid>
      <pubDate>Sun, 16 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>McMillan, Kyle</name>
      </author>
      <author>
        <name>McNitt‐Gray, Michael</name>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
    </item>
    <item>
      <title>A Novel Fast Helical 4D-CT Acquisition Technique to&amp;nbsp;Generate Low-Noise Sorting Artifact–Free Images at&amp;nbsp;User-Selected Breathing Phases</title>
      <link>https://escholarship.org/uc/item/5xb061t3</link>
      <description>PURPOSE: To develop a novel 4-dimensional computed tomography (4D-CT) technique that exploits standard fast helical acquisition, a simultaneous breathing surrogate measurement, deformable image registration, and a breathing motion model to remove sorting artifacts.
METHODS AND MATERIALS: Ten patients were imaged under free-breathing conditions 25 successive times in alternating directions with a 64-slice CT scanner using a low-dose fast helical protocol. An abdominal bellows was used as a breathing surrogate. Deformable registration was used to register the first image (defined as the reference image) to the subsequent 24 segmented images. Voxel-specific motion model parameters were determined using a breathing motion model. The tissue locations predicted by the motion model in the 25 images were compared against the deformably registered tissue locations, allowing a model prediction error to be evaluated. A low-noise image was created by averaging the 25 images deformed to the...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5xb061t3</guid>
      <pubDate>Sun, 16 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Thomas, David</name>
      </author>
      <author>
        <name>Lamb, James</name>
      </author>
      <author>
        <name>White, Benjamin</name>
      </author>
      <author>
        <name>Jani, Shyam</name>
      </author>
      <author>
        <name>Gaudio, Sergio</name>
      </author>
      <author>
        <name>Lee, Percy</name>
      </author>
      <author>
        <name>Ruan, Dan</name>
        <uri>https://orcid.org/0000-0003-3400-7684</uri>
      </author>
      <author>
        <name>McNitt-Gray, Michael</name>
        <uri>https://orcid.org/0000-0003-3004-4613</uri>
      </author>
      <author>
        <name>Low, Daniel</name>
        <uri>https://orcid.org/0000-0002-6425-9228</uri>
      </author>
    </item>
    <item>
      <title>Superior semicircular canal dehiscence postoperative outcomes: a case series of 350 repairs</title>
      <link>https://escholarship.org/uc/item/3mn5j112</link>
      <description>BackgroundSuperior Semicircular Canal Dehiscence (SSCD) is a dehiscence of the otic capsule which normally lies over the superior semicircular canal. This database constitutes the largest series of SSCD patients to date.ObjectiveTo determine what preoperative factors, if any, contribute to postoperative outcomes and evaluate symptom resolution in a large SSCD patient cohort.MethodsA single-institution, retrospective chart review collected patient demographics, intraoperative findings, and pre-and postoperative symptoms. Fisher's exact t-test was performed for unpaired categorical variables, with a significance level of p &amp;lt; 0.05.Results350 SSCD repairs were performed. The median age was 52&amp;nbsp;years (range: 17—86&amp;nbsp;years, ± 6.4&amp;nbsp;years), and the median follow-up duration was 4.6&amp;nbsp;months (range: 0.03—59.5&amp;nbsp;months, ± 6.8&amp;nbsp;months). Preoperative hearing loss was significantly associated with female sex (p = 0.0028). The most reported preoperative symptoms were...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3mn5j112</guid>
      <pubDate>Wed, 12 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Mekonnen, Mahlet</name>
      </author>
      <author>
        <name>Lum, Meachelle</name>
      </author>
      <author>
        <name>Duong, Courtney</name>
      </author>
      <author>
        <name>Rana, Shivam</name>
      </author>
      <author>
        <name>Mozaffari, Khashayar</name>
      </author>
      <author>
        <name>Hovis, Gabrielle EA</name>
      </author>
      <author>
        <name>Yang, Isaac</name>
        <uri>https://orcid.org/0000-0002-5176-5615</uri>
      </author>
    </item>
    <item>
      <title>TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial</title>
      <link>https://escholarship.org/uc/item/1vj0c8bj</link>
      <description>In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas. The primary endpoints were to assess the most effective combination of vaccine and adjuvant in order to enhance the immune potency, along with safety. The combination of ATL-DC vaccination and TLR agonist was safe and found to enhance systemic immune responses, as indicated by increased interferon gene expression and changes in immune cell activation. Specifically, PD-1 expression increases on CD4+ T-cells, while CD38 and CD39 expression are reduced on CD8+ T cells, alongside an increase in monocytes. Poly-ICLC treatment amplifies the induction of interferon-induced genes in monocytes and T lymphocytes. Patients that exhibit higher interferon response gene expression demonstrate prolonged survival and...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1vj0c8bj</guid>
      <pubDate>Mon, 10 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Everson, Richard G</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Hugo, Willy</name>
        <uri>https://orcid.org/0000-0002-1426-7190</uri>
      </author>
      <author>
        <name>Sun, Lu</name>
      </author>
      <author>
        <name>Antonios, Joseph</name>
      </author>
      <author>
        <name>Lee, Alexander</name>
      </author>
      <author>
        <name>Ding, Lizhong</name>
      </author>
      <author>
        <name>Bu, Melissa</name>
      </author>
      <author>
        <name>Khattab, Sara</name>
      </author>
      <author>
        <name>Chavez, Carolina</name>
      </author>
      <author>
        <name>Billingslea-Yoon, Emma</name>
      </author>
      <author>
        <name>Salazar, Andres</name>
      </author>
      <author>
        <name>Ellingson, Benjamin M</name>
      </author>
      <author>
        <name>Cloughesy, Timothy F</name>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Prins, Robert M</name>
        <uri>https://orcid.org/0000-0002-6282-6583</uri>
      </author>
    </item>
    <item>
      <title>Examining the Association between Abstinence from Smoking and Healthcare Costs among Patients with Cancer.</title>
      <link>https://escholarship.org/uc/item/3g0746v6</link>
      <description>Continuous tobacco use in patients with cancer is linked to substantial healthcare costs due to increased risks and complications, whereas quitting smoking leads to improved treatment outcomes and cost reductions. Addressing the need for empirical evidence on the economic impact of smoking cessation, this study examined the association between smoking cessation and healthcare cost utilization among a sample of 930 patients with cancer treated at The University of Texas MD Anderson Cancer Center's Tobacco Research and Treatment Program (TRTP). Applying conditional quantile regression and propensity scores to address confounding, our findings revealed that abstinence achieved through the TRTP significantly reduced the median cost during a 3-month period post-quitting by $1,095 [β = -$1,095, P = 0.007, 95% confidence interval (CI), = (-$1,886 to -$304)]. Sensitivity analysis corroborated these conclusions, showing a pronounced cost reduction when outlier data were excluded. The long-term...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3g0746v6</guid>
      <pubDate>Tue, 4 Jun 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Kypriotakis, George</name>
      </author>
      <author>
        <name>Kim, Seokhun</name>
      </author>
      <author>
        <name>Karam-Hage, Maher</name>
      </author>
      <author>
        <name>Robinson, Jason D</name>
      </author>
      <author>
        <name>Minnix, Jennifer A</name>
      </author>
      <author>
        <name>Blalock, Janice A</name>
      </author>
      <author>
        <name>Cui, Yong</name>
      </author>
      <author>
        <name>Beneventi, Diane</name>
      </author>
      <author>
        <name>Kim, Bumyang</name>
      </author>
      <author>
        <name>Pan, I-Wen</name>
      </author>
      <author>
        <name>Shih, Ya-Chen Tina</name>
        <uri>https://orcid.org/0000-0002-9454-4337</uri>
      </author>
      <author>
        <name>Cinciripini, Paul M</name>
      </author>
    </item>
    <item>
      <title>Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI</title>
      <link>https://escholarship.org/uc/item/3mv0f0pg</link>
      <description>ObjectiveTo determine the feasibility and biologic correlations of dynamic susceptibility contrast (DSC), dynamic contrast enhanced (DCE), and quantitative maps derived from contrast leakage effects obtained simultaneously in gliomas using dynamic spin-and-gradient-echo echoplanar imaging (dynamic SAGE-EPI) during a single contrast injection.Materials and methodsThirty-eight patients with enhancing brain gliomas were prospectively imaged with dynamic SAGE-EPI, which was processed to compute traditional DSC metrics (normalized relative cerebral blood flow [nrCBV], percentage of signal recovery [PSR]), DCE metrics (volume transfer constant [Ktrans], extravascular compartment [ve]), and leakage effect metrics: ΔR2,ss* (reflecting T2*-leakage effects), ΔR1,ss (reflecting T1-leakage effects), and the transverse relaxivity at tracer equilibrium (TRATE, reflecting the balance between ΔR2,ss* and ΔR1,ss). These metrics were compared between patient subgroups (treatment-naïve [TN] vs recurrent...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3mv0f0pg</guid>
      <pubDate>Tue, 28 May 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Sanvito, Francesco</name>
        <uri>https://orcid.org/0000-0003-3379-9958</uri>
      </author>
      <author>
        <name>Raymond, Catalina</name>
      </author>
      <author>
        <name>Cho, Nicholas S</name>
      </author>
      <author>
        <name>Yao, Jingwen</name>
      </author>
      <author>
        <name>Hagiwara, Akifumi</name>
      </author>
      <author>
        <name>Orpilla, Joey</name>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Everson, Richard G</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Nghiemphu, Phioanh L</name>
        <uri>https://orcid.org/0000-0003-4064-6079</uri>
      </author>
      <author>
        <name>Lai, Albert</name>
      </author>
      <author>
        <name>Prins, Robert</name>
      </author>
      <author>
        <name>Salamon, Noriko</name>
        <uri>https://orcid.org/0000-0002-3520-9467</uri>
      </author>
      <author>
        <name>Cloughesy, Timothy F</name>
      </author>
      <author>
        <name>Ellingson, Benjamin M</name>
      </author>
    </item>
    <item>
      <title>Results of an Artificial Intelligence-Based Image Review System to Detect Patient Misalignment Errors in a Multi-institutional Database of Cone Beam Computed Tomography-Guided Radiation Therapy</title>
      <link>https://escholarship.org/uc/item/8c09r991</link>
      <description>PURPOSE: Present knowledge of patient setup and alignment errors in image guided radiation therapy (IGRT) relies on voluntary reporting, which is thought to underestimate error frequencies. A manual retrospective patient-setup misalignment error search is infeasible owing to the bulk of cases to be reviewed. We applied a deep learning-based misalignment error detection algorithm (EDA) to perform a fully automated retrospective error search of clinical IGRT databases and determine an absolute gross patient misalignment error rate.
METHODS AND MATERIALS: The EDA was developed to analyze the registration between planning scans and pretreatment cone beam computed tomography scans, outputting a misalignment score ranging from 0 (most unlikely) to 1 (most likely). The algorithm was trained using simulated translational errors on a data set obtained from 680 patients treated at 2 radiation therapy clinics between 2017 and 2022. A receiver operating characteristic analysis was performed...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8c09r991</guid>
      <pubDate>Wed, 8 May 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Luximon, Dishane C</name>
        <uri>https://orcid.org/0000-0003-0568-5865</uri>
      </author>
      <author>
        <name>Neylon, Jack</name>
      </author>
      <author>
        <name>Ritter, Timothy</name>
      </author>
      <author>
        <name>Agazaryan, Nzhde</name>
      </author>
      <author>
        <name>Hegde, John V</name>
      </author>
      <author>
        <name>Steinberg, Michael L</name>
      </author>
      <author>
        <name>Low, Daniel A</name>
      </author>
      <author>
        <name>Lamb, James M</name>
      </author>
    </item>
    <item>
      <title>Automated detection of vertebral body misalignments in orthogonal kV and MV guided radiotherapy: application to a comprehensive retrospective dataset</title>
      <link>https://escholarship.org/uc/item/4r42d56f</link>
      <description>&lt;i&gt;Objective&lt;/i&gt;. In image-guided radiotherapy (IGRT), off-by-one vertebral body misalignments are rare but potentially catastrophic. In this study, a novel detection method for such misalignments in IGRT was investigated using densely-connected convolutional networks (DenseNets) for applications towards real-time error prevention and retrospective error auditing.&lt;i&gt;Approach&lt;/i&gt;. A total of 4213 images acquired from 527 radiotherapy patients aligned with planar kV or MV radiographs were used to develop and test error-detection software modules. Digitally reconstructed radiographs (DRRs) and setup images were retrieved and co-registered according to the clinically applied alignment contained in the DICOM REG files. A semi-automated algorithm was developed to simulate patient positioning errors on the anterior-posterior (AP) and lateral (LAT) images shifted by one vertebral body. A DenseNet architecture was designed to classify either AP images individually or AP and LAT image pairs....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4r42d56f</guid>
      <pubDate>Wed, 8 May 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Charters, John A</name>
      </author>
      <author>
        <name>Luximon, Dishane</name>
        <uri>https://orcid.org/0000-0003-0568-5865</uri>
      </author>
      <author>
        <name>Petragallo, Rachel</name>
      </author>
      <author>
        <name>Neylon, Jack</name>
      </author>
      <author>
        <name>Low, Daniel A</name>
      </author>
      <author>
        <name>Lamb, James M</name>
      </author>
    </item>
    <item>
      <title>Clinical physicists’ perceptions of weekly chart checks and the potential role for automated image review assessed by structured interviews</title>
      <link>https://escholarship.org/uc/item/3zn6v0wg</link>
      <description>BACKGROUND: This study utilizes interviews of clinical medical physicists to investigate self-reported shortcomings of the current weekly chart check workflow and opportunities for improvement.
METHODS: Nineteen medical physicists were recruited for a 30-minute semi-structured interview, with a particular focus placed on image review and the use of automated tools for image review in weekly checks. Survey-type questions were used to gather quantitative information about chart check practices and importance placed on reducing chart check workloads versus increasing chart check effectiveness. Open-ended questions were used to probe respondents about their current weekly chart check workflow, opinions of the value of weekly chart checks and perceived shortcomings, and barriers and facilitators to the implementation of automated chart check tools. Thematic analysis was used to develop common themes across the interviews.
RESULTS: Physicists ranked highly the value of reducing the...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3zn6v0wg</guid>
      <pubDate>Wed, 8 May 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Petragallo, Rachel</name>
      </author>
      <author>
        <name>Luximon, Dishane C</name>
        <uri>https://orcid.org/0000-0003-0568-5865</uri>
      </author>
      <author>
        <name>Neylon, Jack</name>
      </author>
      <author>
        <name>Bardach, Naomi S</name>
        <uri>https://orcid.org/0000-0002-5178-0719</uri>
      </author>
      <author>
        <name>Ritter, Timothy</name>
      </author>
      <author>
        <name>Lamb, James M</name>
      </author>
    </item>
    <item>
      <title>Development and interinstitutional validation of an automatic vertebral‐body misalignment error detector for cone‐beam CT‐guided radiotherapy</title>
      <link>https://escholarship.org/uc/item/2h86v1r2</link>
      <description>BACKGROUND: In cone-beam computed tomography (CBCT)-guided radiotherapy, off-by-one vertebral-body misalignments are rare but serious errors that lead to wrong-site treatments.
PURPOSE: An automatic error detection algorithm was developed that uses a three-branch convolutional neural network error detection model (EDM) to detect off-by-one vertebral-body misalignments using planning computed tomography (CT) images and setup CBCT images.
METHODS: Algorithm training and test data consisted of planning CTs and CBCTs from 480 patients undergoing radiotherapy treatment in the thoracic and abdominal regions at two radiotherapy clinics. The clinically applied registration was used to derive true-negative (no error) data. The setup and planning images were then misaligned by one vertebral-body in both the superior and inferior directions, simulating the most likely misalignment scenarios. For each of the aligned and misaligned 3D image pairs, 2D slice pairs were automatically extracted...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2h86v1r2</guid>
      <pubDate>Wed, 8 May 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Luximon, Dishane C</name>
        <uri>https://orcid.org/0000-0003-0568-5865</uri>
      </author>
      <author>
        <name>Ritter, Timothy</name>
      </author>
      <author>
        <name>Fields, Emma</name>
      </author>
      <author>
        <name>Neylon, John</name>
      </author>
      <author>
        <name>Petragallo, Rachel</name>
      </author>
      <author>
        <name>Abdulkadir, Yasin</name>
      </author>
      <author>
        <name>Charters, John</name>
      </author>
      <author>
        <name>Low, Daniel A</name>
        <uri>https://orcid.org/0000-0002-6425-9228</uri>
      </author>
      <author>
        <name>Lamb, James M</name>
      </author>
    </item>
    <item>
      <title>Impact of PSMA PET on Prostate Cancer Management</title>
      <link>https://escholarship.org/uc/item/3f5607n3</link>
      <description>Opinion statementPSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3f5607n3</guid>
      <pubDate>Tue, 7 May 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Weiner, Adam B</name>
      </author>
      <author>
        <name>Agrawal, Raag</name>
        <uri>https://orcid.org/0000-0001-8222-3117</uri>
      </author>
      <author>
        <name>Valle, Luca F</name>
        <uri>https://orcid.org/0000-0002-5781-4174</uri>
      </author>
      <author>
        <name>Sonni, Ida</name>
      </author>
      <author>
        <name>Kishan, Amar U</name>
      </author>
      <author>
        <name>Rettig, Matthew B</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Raman, Steven S</name>
        <uri>https://orcid.org/0000-0003-0499-1676</uri>
      </author>
      <author>
        <name>Calais, Jeremie</name>
        <uri>https://orcid.org/0000-0002-8839-4379</uri>
      </author>
      <author>
        <name>Boutros, Paul C</name>
        <uri>https://orcid.org/0000-0003-0553-7520</uri>
      </author>
      <author>
        <name>Reiter, Robert E</name>
      </author>
    </item>
    <item>
      <title>Prospective investigation of patent foramen ovale as a mechanism for brain metastasis in patients without prior lung involvement.</title>
      <link>https://escholarship.org/uc/item/7xw2953v</link>
      <description>Prospective investigation of patent foramen ovale as a mechanism for brain metastasis in patients without prior lung involvement.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7xw2953v</guid>
      <pubDate>Wed, 1 May 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Levin-Epstein, Rebecca</name>
      </author>
      <author>
        <name>Rusheen, Joshua</name>
      </author>
      <author>
        <name>Kumar, Preetham</name>
      </author>
      <author>
        <name>Gevorgyan, Rubine</name>
      </author>
      <author>
        <name>McWatters, Zoe</name>
      </author>
      <author>
        <name>Kim, Won</name>
        <uri>https://orcid.org/0000-0003-3423-3825</uri>
      </author>
      <author>
        <name>Kaprealian, Tania Betty</name>
      </author>
      <author>
        <name>West, Brian</name>
      </author>
      <author>
        <name>Tobis, Jonathan</name>
        <uri>https://orcid.org/0000-0003-2462-3459</uri>
      </author>
    </item>
    <item>
      <title>Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.</title>
      <link>https://escholarship.org/uc/item/10n0m73x</link>
      <description>PURPOSE: Antiangiogenic therapies are known to cause high radiographic response rates due to reduction in vascular permeability resulting in a lower degree of contrast extravasation. In this study, we investigate the prognostic ability for model-derived parameters describing enhancing tumor volumetric dynamics to predict survival in recurrent glioblastoma treated with antiangiogenic therapy.
EXPERIMENTAL DESIGN: N = 276 patients in two phase II trials were used as training data, including bevacizumab ± irinotecan (NCT00345163) and cabozantinib (NCT00704288), and N = 74 patients in the bevacizumab arm of a phase III trial (NCT02511405) were used for validation. Enhancing volumes were estimated using T1 subtraction maps, and a biexponential model was used to estimate regrowth (g) and regression (d) rates, time to tumor regrowth (TTG), and the depth of response (DpR). Response characteristics were compared to diffusion MR phenotypes previously shown to predict survival.
RESULTS:...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/10n0m73x</guid>
      <pubDate>Wed, 1 May 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Ellingson, Benjamin M</name>
      </author>
      <author>
        <name>Hagiwara, Akifumi</name>
      </author>
      <author>
        <name>Morris, Connor J</name>
        <uri>https://orcid.org/0000-0002-0754-0670</uri>
      </author>
      <author>
        <name>Cho, Nicholas S</name>
      </author>
      <author>
        <name>Oshima, Sonoko</name>
      </author>
      <author>
        <name>Sanvito, Francesco</name>
        <uri>https://orcid.org/0000-0003-3379-9958</uri>
      </author>
      <author>
        <name>Oughourlian, Talia C</name>
        <uri>https://orcid.org/0000-0001-8133-2928</uri>
      </author>
      <author>
        <name>Telesca, Donatello</name>
      </author>
      <author>
        <name>Raymond, Catalina</name>
      </author>
      <author>
        <name>Abrey, Lauren E</name>
      </author>
      <author>
        <name>Garcia, Josep</name>
      </author>
      <author>
        <name>Aftab, Dana T</name>
      </author>
      <author>
        <name>Hessel, Colin</name>
      </author>
      <author>
        <name>Rachmilewitz Minei, Tamar</name>
      </author>
      <author>
        <name>Harats, Dror</name>
      </author>
      <author>
        <name>Nathanson, David A</name>
      </author>
      <author>
        <name>Wen, Patrick Y</name>
      </author>
      <author>
        <name>Cloughesy, Timothy F</name>
      </author>
    </item>
    <item>
      <title>Deep match: A zero-shot framework for improved fiducial-free respiratory motion tracking</title>
      <link>https://escholarship.org/uc/item/7q94b5dr</link>
      <description>BACKGROUND AND PURPOSE: Motion management is essential to reduce normal tissue exposure and maintain adequate tumor dose in lung stereotactic body radiation therapy (SBRT). Lung SBRT using an articulated robotic arm allows dynamic tracking during radiation dose delivery. Two stereoscopic X-ray tracking modes are available - fiducial-based and fiducial-free tracking. Although X-ray detection of implanted fiducials is robust, the implantation procedure is invasive and inapplicable to some patients and tumor locations. Fiducial-free tracking relies on tumor contrast, which challenges the existing tracking algorithms for small (e.g., &amp;lt;15&amp;nbsp;mm) and/or tumors obscured by overlapping anatomies. To markedly improve the performance of fiducial-free tracking, we proposed a deep learning-based template matching algorithm - Deep Match.
METHOD: Deep Match consists of four self-definable stages - training-free feature extractor, similarity measurements for location proposal, local refinements,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7q94b5dr</guid>
      <pubDate>Thu, 25 Apr 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Xu, Di</name>
        <uri>https://orcid.org/0000-0001-5587-5275</uri>
      </author>
      <author>
        <name>Descovich, Martina</name>
      </author>
      <author>
        <name>Liu, Hengjie</name>
        <uri>https://orcid.org/0000-0001-5890-2291</uri>
      </author>
      <author>
        <name>Lao, Yi</name>
      </author>
      <author>
        <name>Gottschalk, Alexander R</name>
      </author>
      <author>
        <name>Sheng, Ke</name>
      </author>
    </item>
    <item>
      <title>One Year Radiographic Response Following Prostrate SBRT: An Exploratory Analysis of a Phase III Randomized Trial</title>
      <link>https://escholarship.org/uc/item/1m333972</link>
      <description>Purpose/Objective(s) Radiographic MRI response following prostate radiotherapy, particularly stereotactic body radiotherapy (SBRT), remains poorly understood. Our objective was to describe radiographic changes to the prostate gland and prostate tumor following SBRT of men treated on a prospective, randomized trial. Materials/Methods MIRAGE (NCT 04384770) is a single center, randomized phase III trial of patients receiving either CT or MRI guided SBRT for localized prostate cancer. Patients underwent pre-treatment and annual post-treatment MRIs, in addition to routine PSA surveillance. Outcomes reported include percent gland shrinkage, percent PSA response at one year, and presence of residual tumor based on radiographic interpretation. Patient characteristics were compared via two-sample t-test or Fischer's exact test. Both univariate and multivariable logistical analysis were employed to identify potential clinical predictors of residual tumor on 1-year follow up MRI. Results...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1m333972</guid>
      <pubDate>Wed, 24 Apr 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Jiang, T</name>
      </author>
      <author>
        <name>Valle, L</name>
        <uri>https://orcid.org/0000-0002-5781-4174</uri>
      </author>
      <author>
        <name>Steinberg, ML</name>
      </author>
      <author>
        <name>Reiter, RE</name>
      </author>
      <author>
        <name>Rettig, M</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Nickols, NG</name>
      </author>
      <author>
        <name>Casado, M</name>
      </author>
      <author>
        <name>Lamb, JM</name>
      </author>
      <author>
        <name>Cao, M</name>
      </author>
      <author>
        <name>Raman, S</name>
        <uri>https://orcid.org/0000-0003-0499-1676</uri>
      </author>
      <author>
        <name>Sung, KH</name>
        <uri>https://orcid.org/0000-0003-4175-5322</uri>
      </author>
      <author>
        <name>Romero, T</name>
      </author>
      <author>
        <name>Kishan, AU</name>
      </author>
    </item>
    <item>
      <title>Radiographic-pathologic concordance in the workup of locally radiorecurrent prostate cancer.</title>
      <link>https://escholarship.org/uc/item/0wr6x9pj</link>
      <description>313  
 Background: Advanced molecular PET/CT (mPET) studies are increasingly being utilized in conjunction with multiparametric MRI (mpMRI) to evaluate the burden of radiorecurrent disease in men who develop a biochemical recurrence following definitive radiotherapy (RT) for prostate cancer (PCa). However, radiographic concordance with pathologic confirmation of radiorecurrent disease in this setting is poorly described. We sought to conduct a patient-level analysis comparing concordance of radiographic and pathologic findings between mpMRI and mPET. Methods: Men who had previously undergone definitive RT for PCa and subsequently experienced treatment failure defined by the Phoenix definition were enrolled in a prospective registry study wherein radiographically identified local PCa recurrences were biopsied using mpMRI or mPET fusion (Artemis) with real-time ultrasound. Prior to biopsy, men underwent diagnostic imaging with mpMRI, advanced mPET (68Ga-PSMA-11 or 18F-FACBC), or...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0wr6x9pj</guid>
      <pubDate>Wed, 24 Apr 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Valle, Luca Faustino</name>
        <uri>https://orcid.org/0000-0002-5781-4174</uri>
      </author>
      <author>
        <name>Calais, Jeremie</name>
        <uri>https://orcid.org/0000-0002-8839-4379</uri>
      </author>
      <author>
        <name>Marks, Leonard S</name>
      </author>
      <author>
        <name>Raman, Steven</name>
        <uri>https://orcid.org/0000-0003-0499-1676</uri>
      </author>
      <author>
        <name>Reiter, Robert Evan</name>
      </author>
      <author>
        <name>Rettig, Matthew</name>
        <uri>https://orcid.org/0000-0002-7394-3056</uri>
      </author>
      <author>
        <name>Shen, John</name>
        <uri>https://orcid.org/0000-0002-6455-5553</uri>
      </author>
      <author>
        <name>Czernin, Johannes</name>
      </author>
      <author>
        <name>Weiner, Adam B</name>
      </author>
      <author>
        <name>Steinberg, Michael L</name>
      </author>
      <author>
        <name>Nickols, Nicholas George</name>
      </author>
      <author>
        <name>Chang, Albert J</name>
      </author>
      <author>
        <name>Boutros, Paul Christopher</name>
        <uri>https://orcid.org/0000-0003-0553-7520</uri>
      </author>
      <author>
        <name>Ye, Huihui</name>
      </author>
      <author>
        <name>Hotta, Masatoshi</name>
      </author>
      <author>
        <name>Huang, Rong Rong</name>
      </author>
      <author>
        <name>Kishan, Amar Upadhyaya</name>
      </author>
    </item>
    <item>
      <title>Single-nucleus expression characterization of non-enhancing region of recurrent high-grade glioma</title>
      <link>https://escholarship.org/uc/item/6p12x6ft</link>
      <description>Background: Non-enhancing (NE) infiltrating tumor cells beyond the contrast-enhancing (CE) bulk of tumor are potential propagators of recurrence after gross total resection of high-grade glioma.
Methods: We leveraged single-nucleus RNA sequencing on 15 specimens from recurrent high-grade gliomas (&lt;i&gt;n&lt;/i&gt; = 5) to compare prospectively identified biopsy specimens acquired from CE and NE regions. Additionally, 24 CE and 22 NE biopsies had immunohistochemical staining to validate RNA findings.
Results: Tumor cells in NE regions are enriched in neural progenitor cell-like cellular states, while CE regions are enriched in mesenchymal-like states. NE glioma cells have similar proportions of proliferative and putative glioma stem cells relative to CE regions, without significant differences in % Ki-67 staining. Tumor cells in NE regions exhibit upregulation of genes previously associated with lower grade gliomas. Our findings in recurrent GBM paralleled some of the findings in a re-analysis...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6p12x6ft</guid>
      <pubDate>Mon, 22 Apr 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Patel, Kunal S</name>
      </author>
      <author>
        <name>Tessema, Kaleab K</name>
      </author>
      <author>
        <name>Kawaguchi, Riki</name>
      </author>
      <author>
        <name>Dudley, Lindsey</name>
      </author>
      <author>
        <name>Alvarado, Alvaro G</name>
        <uri>https://orcid.org/0000-0002-4049-8400</uri>
      </author>
      <author>
        <name>Muthukrishnan, Sree Deepthi</name>
      </author>
      <author>
        <name>Perryman, Travis</name>
      </author>
      <author>
        <name>Hagiwara, Akifumi</name>
      </author>
      <author>
        <name>Swarup, Vivek</name>
      </author>
      <author>
        <name>Liau, Linda M</name>
        <uri>https://orcid.org/0000-0002-4053-0052</uri>
      </author>
      <author>
        <name>Wang, Anthony C</name>
        <uri>https://orcid.org/0000-0002-9509-6257</uri>
      </author>
      <author>
        <name>Yong, William</name>
        <uri>https://orcid.org/0000-0002-0879-0209</uri>
      </author>
      <author>
        <name>Geschwind, Daniel H</name>
      </author>
      <author>
        <name>Nakano, Ichiro</name>
      </author>
      <author>
        <name>Goldman, Steven A</name>
      </author>
      <author>
        <name>Everson, Richard G</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Ellingson, Benjamin M</name>
      </author>
      <author>
        <name>Kornblum, Harley I</name>
      </author>
    </item>
    <item>
      <title>Investigation of patent foramen ovale as a mechanism for brain metastasis in patients without prior lung involvement</title>
      <link>https://escholarship.org/uc/item/5v68b871</link>
      <description>PurposeThe mechanisms of brain metastasis are incompletely understood. Circulating tumor cells travel to the right heart and through the pulmonary circulation, where they may become lung metastases, and can circulate further to the left heart and brain. In patients who develop brain metastases without lung involvement, we hypothesized that cancer cells may travel directly from the right atrium to left atrium via a patent foramen ovale (PFO), akin to paradoxical embolism. If the prevalence of PFO is greater in these individuals compared to the general population (20–30%), PFO may play a role in brain metastasis, and prophylactic closure may provide benefit. Accordingly, we investigated the prevalence of PFO in patients with brain metastases without prior lung involvement.MethodsWe prospectively identified patients with brain metastases from a non-lung primary cancer with no preceding or concurrent lung involvement. Nine eligible participants underwent a transcranial Doppler study...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5v68b871</guid>
      <pubDate>Mon, 22 Apr 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Levin-Epstein, R</name>
      </author>
      <author>
        <name>Kumar, P</name>
      </author>
      <author>
        <name>Rusheen, J</name>
      </author>
      <author>
        <name>Fleming, RG</name>
      </author>
      <author>
        <name>McWatters, Z</name>
      </author>
      <author>
        <name>Kim, W</name>
        <uri>https://orcid.org/0000-0003-3423-3825</uri>
      </author>
      <author>
        <name>Kaprealian, TB</name>
      </author>
      <author>
        <name>West, B</name>
      </author>
      <author>
        <name>Tobis, JM</name>
        <uri>https://orcid.org/0000-0003-2462-3459</uri>
      </author>
    </item>
    <item>
      <title>Cervicomedullary junction mature teratoma with pulmonary differentiation and diastematomyelia in an adult – A rare case</title>
      <link>https://escholarship.org/uc/item/0bh893c4</link>
      <description>Background: Intradural extramedullary teratomas in the cervical or cervicomedullary region are rare in adults.
Case Description: We report a symptomatic, mature teratoma at the cervicomedullary junction in a 52-year-old Hispanic female who also has a type I diastematomyelia in the thoracolumbar spine. The patient underwent surgical resection of the lesion with the resolution of presenting symptoms. Histopathology of the lesion revealed a mature cystic teratoma with pulmonary differentiation.
Conclusion: We discuss the case along with a review of pertinent literature and considerations with regard to the diagnosis, etiology, prognosis, and management of this unusual pathology.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0bh893c4</guid>
      <pubDate>Fri, 12 Apr 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Peeters, Sophie M</name>
      </author>
      <author>
        <name>Uhr, Lauren</name>
      </author>
      <author>
        <name>Chivukula, Srinivas</name>
      </author>
      <author>
        <name>McBride, Duncan</name>
      </author>
      <author>
        <name>Everson, Richard</name>
        <uri>https://orcid.org/0000-0003-2809-3061</uri>
      </author>
      <author>
        <name>Duong, Duc</name>
      </author>
      <author>
        <name>Yang, Isaac</name>
      </author>
      <author>
        <name>Cornford, Marcia</name>
      </author>
      <author>
        <name>Mlikotic, Anton</name>
      </author>
      <author>
        <name>Yong, William</name>
        <uri>https://orcid.org/0000-0002-0879-0209</uri>
      </author>
      <author>
        <name>Kim, Won</name>
      </author>
    </item>
  </channel>
</rss>
